or˛anˆˇ - center for international blood and marrow ...€¦ · transplant nurses, clinical...

BMT TANDEMMEETINGSComprehensive Update on Blood and Marrow Transplantation• Laboratory Research • Clinical Investigations • Patient Care

February 22-26 2017

OrlandoFlorida

PROGRAM GUIDEUPDATED FEB 22, 2017

to improving the care of transplant patients

COMMITTEDWe are

Sano� Genzyme is

YOUR PARTNER IN TRANSPLANTATION

US.PLE.16.12.002© 2002-2017 sano� -aventis U.S. LLC. All rights reserved.

ii

WelcomeOn behalf of the Organizing Committee, we extend our warm welcome as you arrive for the 2017 BMT Tandem Meetings in Orlando. Our five days of plenary sessions, concurrent scientific and oral abstract sessions, Meet-the-Professor lunches and symposia will present recent progress in basic science, translational research and clinical studies in all areas of blood and marrow transplantation and cellular therapy.

This year we expect more than 3,200 attendees and are proud to have 569 abstracts submitted by authors from more than 25 countries. Registered attendees have the option to view an electronic copy or hard copy of the official supplement to the March 2017 issue of Biology of Blood and Marrow Transplantation containing each of the accepted abstracts presented at the meeting. The abstract supplement also features a review article highlighting one of the scientific sessions.

In keeping with a growing tradition, eleven parallel conferences of specialized sessions will be attended by more than 1,400 transplant nurses, clinical research professionals, BMT pharmacists, BMT center administrators, and advanced practice professionals. We continue to host a Pediatric BMT Program on Thursday that highlights the specific issues of cellular therapy in children and adolescents.

Special thanks to our corporate partners, without whom we would not be able to provide this important international forum for the science and practice of hematopoietic stem cell therapy. They continue to support our meetings through their grants and exhibits and we are truly grateful for their enduring loyalty.

We wish you a productive and stimulating time at the BMT Tandem Meetings and an enjoyable stay in sunny Florida.

Very sincerely,

Marcel R.M. van den Brink, MD, PhD Memorial Sloan Kettering Cancer Center New York, NY Program Co-Chair, ASBMT

David I. Marks, MBBS, PhD University Hospitals Bristol NHS Trust Bristol, United Kingdom Program Co-Chair, CIBMTR

Join the conversation on Twitter: #BMTTandem17

iii

Table of ContentsBMT Tandem Meetings Scientific Organizing Committee . .1Target Audience. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1Educational Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1Continuing Medical and Professional Education. . . . . . . . . .2 ACCME Accreditation Statement . . . . . . . . . . . . . . . . . . . . .2 AMA Credit Designation Statement . . . . . . . . . . . . . . . . . . .2 Hours of Participation for Allied Health Professionals . . . . . . .2 CME Certificate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 Certificate of Attendance . . . . . . . . . . . . . . . . . . . . . . . . . . . .2Pharmacist Education . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3Nursing Education . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3Faculty Disclosure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3General Information

Abstract Book. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4Attire . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .42017 BMT Tandem Reception . . . . . . . . . . . . . . . . . . . . . . . .4Breakfast and Lunch Options . . . . . . . . . . . . . . . . . . . . . . . . .4Business Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4Conference Registration Desk . . . . . . . . . . . . . . . . . . . . . . . . .5Emergency Planning . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5Getting Around Orlando . . . . . . . . . . . . . . . . . . . . . . . . . . . .5Internet Access Center and Charging Lounge . . . . . . . . . . . . .6Lost and Found . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6Meeting Locations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6Meet-the-Professor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . .7Mobile App . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8Name Badges. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8Physician Payments Sunshine Act . . . . . . . . . . . . . . . . . . . . . .8

Posters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8 Recordings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9

Research Statistics Consultation . . . . . . . . . . . . . . . . . . . . . . .9Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9

Wi-Fi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9Product Theaters. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .10Corporate Support . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .11ASBMT Leadership . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .14CIBMTR Leadership . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .15ASBMT Travel Grant Recipients . . . . . . . . . . . . . . . . . . . . .17

iv

Pre-Conference AgendaMonday, February 20 . . . . . . . . . . . . . . . . . . . . . . . . . . . .18

Tuesday, February 21 . . . . . . . . . . . . . . . . . . . . . . . . . . . .18Conference Agenda

Wednesday, February 22. . . . . . . . . . . . . . . . . . . . . . . . . .20 Poster Session I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .30Thursday, February 23 . . . . . . . . . . . . . . . . . . . . . . . . . . .31 Pediatric BMT Program . . . . . . . . . . . . . . . . . . . . . . .36Friday, February 24 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .47

Best Abstracts Session . . . . . . . . . . . . . . . . . . . . . . . . . .55CIBMTR Awards. . . . . . . . . . . . . . . . . . . . . . . . . . . . .56ASBMT Awards . . . . . . . . . . . . . . . . . . . . . . . . . . . . .58Mortimer M. Bortin Lecture . . . . . . . . . . . . . . . . . . . .60E. Donnall Thomas Lecture . . . . . . . . . . . . . . . . . . . . .61

Saturday, February 25 . . . . . . . . . . . . . . . . . . . . . . . . . . . .62Poster Session II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .73BMT Tandem Meetings Reception. . . . . . . . . . . . . . . . .73

Sunday, February 26 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .74CIBMTR Clinical Research Professionals/

Data Management Conference. . . . . . . . . . . . . . . . . . . . .77CRP/DM In-Depth Training . . . . . . . . . . . . . . . . . . . . . . . .80BMT CTN Investigators Meeting . . . . . . . . . . . . . . . . . . . .81BMT CTN Coordinators Meeting . . . . . . . . . . . . . . . . . . .82Building a Patient-Centered Outcomes Research

(PCOR) Collaborative Community . . . . . . . . . . . . . . . . .85Administrative Directors Conference. . . . . . . . . . . . . . . . . .87HCT Value and Health Economics Session. . . . . . . . . . . . .90BMT Clinical Education Conference

(for NPs, PAs, Fellows and Junior Faculty) . . . . . . . . . . .91BMT Pharmacists Conference . . . . . . . . . . . . . . . . . . . . . . .95Transplant Nursing Conference . . . . . . . . . . . . . . . . . . . . . .982016-2017 ASBMT Committees . . . . . . . . . . . . . . . . . . . .102ASBMT Special Interest Groups . . . . . . . . . . . . . . . . . . . .105CIBMTR Working Committees

Working Committee Meetings Schedule-at-a-Glance . . . . .108 Working Committee Leadership and Staff . . . . . . . . . . . . .110Invited Faculty. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .113All Committee Meetings Schedule-at-a-Glance . . . . . . . .135Special Thanks. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .143Convention Center and Hotel Maps . . . . . . . . . . . . . . . . .146Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .153Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .156

11

BMT Tandem Meetings Scientific Organizing CommitteeProgram Co-Chairs Marcel R.M. van den Brink, MD, PhD, New York, NY (ASBMT)David I. Marks, MBBS, PhD, Bristol, UK (CIBMTR)

Bruce R. Blazar, MD, Minneapolis, MN (ASBMT) Hermann Einsele, MD, Tübingen, Germany (ASBMT)James L.M. Ferrara, MD, DSc, New York, NY (ASBMT)Helen E. Heslop, MD, Houston, TX (CIBMTR)Mary M. Horowitz, MD, MS, Milwaukee, WI (CIBMTR)Yoshihisa Kodera, MD, PhD, Aichi, Japan (CIBMTR)Leo Luznik, MD, Baltimore, MD (ASBMT)Margaret L. MacMillan, MD, MSc, Minneapolis, MN (ASBMT)Paul J. Martin, MD, Seattle, WA (CIBMTR)Shinichiro Okamoto, MD, Tokyo, Japan (ASBMT)Thomas C. Shea, MD, Chapel Hill, NC (CIBMTR)Kirsten M. Williams, MD, Washington, DC (CIBMTR)Mei-Jie Zhang, PhD, Milwaukee, WI (CIBMTR)

Target AudienceHealth professionals with a clinical interest in blood and marrow transplantation and related investigations, advanced practice professionals, laboratory technicians, clinical research professionals, pharmacists, nurses, data managers, BMT center administrators, and other allied health professionals.

Educational Objectives• Report on the state of the art in cellular therapy and blood

and marrow transplantation.• Analyze new methods and controversial issues in clinical

management strategies for reducing toxicity.• Assess new basic science information in areas of

immunogenetics, molecular biology, stem cell biology,and immunology as it relates to hematopoietic stemcell transplantation in the treatment of hematologicmalignancy and solid tumors.

• Review accomplishments of ASBMT, including progresson organizational, societal, and regulatory issues in bloodand marrow transplantation.

• Review CIBMTR research accomplishments and set theorganization’s scientific agenda for next year.

• Report on contemporary principles in BMT nursing,pharmacy, data management, clinical research analysis, andtransplant center administration.

Continuing Medical and Professional EducationThe 2017 BMT Tandem Meetings are sponsored by the Medical College of Wisconsin.

ACCME Accreditation StatementThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

AMA Credit Designation StatementThe Medical College of Wisconsin designates this live activity for a maximum of 47.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health ProfessionalsThe Medical College of Wisconsin designates this activity for up to 36.0 hours of participation for continuing education for allied health professionals attending the Clinical Research Professionals/Data Management Conference, Clinical Education Conference, BMT CTN Coordinators and Investigators Meetings and Health Economics Session (held during the Administrative Directors Conference).

CME CertificateEvaluation Forms and a Session Credit Summary will be available on the 2017 BMT Tandem Meetings Home Page to record the number of credits earned. Kiosks are available at the conference to complete evaluations. CME credit will not be issued without completion of the online evaluation. The CME Certificate, indicating sessions attended and credits earned, will be available for download after online evaluation forms have been completed. An electronic copy of this certificate will be filed with the Medical College of Wisconsin. There is a $60 fee for CME Certificates requested 30 days after the conference concludes. Certificates will not be mailed.

Certificate of AttendanceCertificates of Attendance are complimentary if requested during registration or on-site at the conference. There is a $60 fee for Certificates of Attendance requested after the conference.

2

3

Pharmacist EducationSyntaxx Communications, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Syntaxx Communications has assigned 12.5 contact hours (1.25 CEUs) of continuing pharmacy education credit for this knowledge- and application-based activity. This two-day live conference will incorporate 13 individual activity sessions that combined will fulfill the 12.5 hours of CE. The target audience for this accredited activity is pharmacists. To receive continuing pharmacy education credit for the Conference, participants must attend the sessions in their entirety and complete the associated program evaluation forms.

Additionally, all US-based pharmacists must supply their National Association of Boards of Pharmacy (NABP) electronic Profile Identification (ePID) number and their birth month and day (MM/DD). No credit can or will be issued without this information. To acquire an NABP ePID, go to http://www.nabp.net and click on CPE Monitor. Universal Activity Numbers: 0299-9999-17-001-L01-P through 0299-9999-17-013-L01-P. For questions or issues related to continuing pharmacy education, please contact Syntaxx Communications: [email protected].

Nursing EducationRegistered attendees can earn 17.5 CNE if all educational sessions are attended in their entirety.

The Oncology Nursing Society (ONS) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Nurses can earn up to an additional 3 CNE for viewing the poster abstracts on their own time. For every 19 posters viewed, an additional 1 CNE can be earned.

Faculty DisclosureThe 2017 BMT Tandem Meetings are committed to providing unbiased, balanced, and objective educational and scientific programs. In accordance with ACCME guidelines, all planners and speakers are asked to provide disclosures of their relevant financial relationships, which are available online for audience review. The CME provider has a mechanism in place to identify and resolve any conflicts of interest prior to the start of each presentation. Audience members will be asked to assess each presentation for the presence/absence of commercial bias.

4

General InformationAbstract BookAll accepted abstracts for the BMT Tandem Meetings are published in a supplement to the March 2017 issue of Biology of Blood and Marrow Transplantation (Vol. 23, No. 3, Supplement 1). Registered attendees have the option to view an electronic copy or hard copy of the abstract book.

The Abstract Book is supported by Celgene Corporation.

AttireCasual business or resort wear is appropriate for the entire week at all events, including the Saturday evening BMT Tandem Reception at Gaylord Palms. The Convention Center may be cool in the meeting rooms, requiring a light sweater or jacket.

2017 BMT Tandem ReceptionJoin ASBMT President, Christopher Bredeson, MD, MSc and CIBMTR Chair, Paul J. Martin, MD for an enjoyable evening of conversation, complimentary beverages and cuisine and dancing on Saturday, February 25. The evening will begin on the Coquina Lawn at the Gaylord Palms, then move into Wreckers Nightclub, just off the lawn, for dancing. Tickets are available online and at the Registration Desk until Thursday, February 23 at 5:00 pm, subject to availability.

Breakfast and Lunch Options

Symposia Grab breakfast or lunch in Exhibit Hall F and attend scientific symposia.Committee Meetings Attend a committee meeting, such as one of the CIBMTR Working Committee meetings (open to all attendees) or another meeting to which you have been invited. Meet-the-Professor Lunch Sessions Meet-the-Professor sessions will be held Wednesday through Saturday; tickets are $35 and may be purchased at the Conference Registration Desk (subject to availability). Details on page 7. BMT Tandem Buffet Choose from a selection of continental breakfast and lunch items located in Exhibit Hall F.

Business CenterThe Business Center is located on the Mezzanine Level of the Gaylord Palms Convention Center and is open daily from 7:00 am to 7:00 pm.

GE

NE

RA

L IN

FO

RM

AT

ION

5

Conference Registration DeskThe BMT Tandem Meetings Registration Desk is located in the Florida Exhibit Hall Lobby F, Level 1 of the Gaylord Palms Convention Center. On-site Conference Registration Desk hours are:

Monday, February 20 5:00 pm – 8:00 pm Tuesday, February 21 7:00 am – 6:00 pm Wednesday, February 22 7:00 am – 6:00 pm Thursday, February 23 7:00 am – 6:00 pm Friday, February 24 7:00 am – 6:00 pm Saturday, February 25 7:00 am – 6:00 pm Sunday, February 26 7:00 am – 1:30 pm

For after-hours technical assistance regarding registration, please contact: [email protected].

Emergency PlanningIn the event of an emergency dial “33” on any in-house phone. When reporting an emergency, be sure to stay calm and be prepared to give the following information: • Your name• Exact location where assistance is needed• Nature of emergency• The number of people and, if applicable, injuries of those

involved.

Local Police, Fire and Ambulance: 911.

ExhibitsExhibits will be open Wednesday, February 22, through Saturday, February 25, from 7:00 am to 2:00 pm in Exhibit Hall F, Level 1.

Getting Around OrlandoThe Gaylord Palms Convention Center is easy to access by car, taxi or Uber.

Car Rental Avis offers meeting attendees special discounts on a wide selection of vehicles, from one week before to one week after the BMT Tandem Meetings. To reserve a car, contact Avis at (800) 331-1212 and use the Avis Worldwide Discount (AWD) number S012600. Or reserve online and include the discount number in the reservation to receive an e-mail confirmation.

The 2017 BMT Tandem Meetings have partnered with Advantage Rent A Car to provide a 10% discount to our registrants. Advantage has also agreed to waive the Second Driver fee (a savings of an additional $13/per day.) The discount rate will remain available from February 15th

6

through March 1st. Meeting registrants can visit www.advantage.com/vehicles to place your reservation or contact Advantage at (800) 777-5500 and use the promo code CD06CB077A to take advantage of the discount.

Internet Access Center and Charging LoungeMeeting attendees are invited to make use of the complimentary Internet Access Center, located on Level 2 in the City Hall Lobby of the Gaylord Palms Convention Center.

Complimentary Wi-Fi access is available in all BMT Tandem Meeting rooms at the Gaylord Palms Convention Center. Network Name: BMTTANDEM; Password: BMT2017!

Wi-Fi is available thanks to support from Novartis Pharmaceuticals Corporation.

Meeting attendees are invited to make use of the Charging Lounge with complimentary power strips available to recharge laptop and cell phone batteries, located in the City Hall Lobby of the Gaylord Palms Convention Center.

The Charging Lounge is available thanks to support from Sanofi Genzyme.

Lost and FoundPlease check at the BMT Tandem Meetings Conference Registration Desk for lost items. After the Meetings, remaining items will be left with the Gaylord Palms Convention Center.

Meeting LocationsGaylord Palms Convention Center 6000 West Osceola Parkway, Kissimmee, FL 34746 Telephone: (407) 586-0000 www.marriott.com/hotels/travel/mcogp-gaylord-palms-resort-and-convention-center

Scientific Plenary Sessions Florida Hall E – Level 1

Concurrent Scientific Sessions Florida Halls C, D and E – Level 1

Exhibits Exhibit Hall F – Level 1

Posters Florida Hall B – Level 1

BMT CTN Investigators Sun B – Level 2

BMT CTN Coordinators Sun A – Level 2Clinical Research Professionals /Data Managers

Osceola D – Level 2

Pediatric BMT Program Osceola C – Level 2

GE

NE

RA

L IN

FO

RM

AT

ION

7

Administrative Directors Conference

Sun A – Level 2

Clinical Education Conference Osceola C – Level 2

BMT Pharmacists Conference Osceola A – Level 2

Transplant Nursing Conference Osceola D – Level 2Building a PCOR Collaborative Community

Sun A – Level 2

Meet-the-Professor SessionsFellows and junior faculty have an opportunity for informal discussion with experts in BMT patient management. Each session will feature a case-based discussion led by internationally renowned authorities. Meet-the-Professor Sessions will be held on Wednesday through Saturday and be capped at a maximum of 25 attendees to keep sessions interactive. Tickets are $35 and may be purchased at the Conference Registration Desk, subject to availability.

Wednesday, February 22 12:15 pm – 1:30 pm Evolution and History of HCT . . . . . . . Room Sun 1

Richard J. O'Reilly, MD and Rainer Storb, MDCord Blood Transplant . . . . . . . . . . . . . . Room Sun 2

Juliet N. Barker, MBBSThursday, February 23

12:15 pm – 1:30 pm Unusual Lymphomas and the Role of Autografting and Allografting . . . . . . . . . Room Sun 1

Timothy S. Fenske, MD, MSSelecting an Alternative Donor . . . . . . . Room Sun 2

Bronwen E. Shaw, MD, PhDFriday, February 24

12:15 pm – 1:30 pm All Things HLH . . . . . . . . . . . . . . . . . . . . Room Sun 1

Rebecca A. Marsh, MDSpecial Considerations in HCT for Patients with Sickle Cell Disease . . . . . . Room Sun 2

Nicolas Novitzky, MD, PhDSaturday, February 25

12:15 pm – 1:30 pm How Do I Work-Up and Treat Transplant-Associated Microangiopathy (TAM)? . . Room Sun 1

Joseph H. Antin, MDHow to Propose a Successful Registry Study with CIBMTR . . . . . . . . . . . . . . . . Room Sun 2

Steven M. Devine, MD

8

Mobile AppDownload the official BMT Tandem Meetings app for quick and easy access to the schedule, attendee list, venue information and more! Search for BMT Tandem in your app store, enter bmt2017 for access verification and, after downloading the app, enter the same email address used to register for the meeting for additional features. The app is free for all registered attendees. With Wi-Fi available throughout all BMT Tandem meeting rooms, users can:

• View and search the meeting program schedule• Vote/participate in interactive sessions• Complete session evaluations• Search for speakers• Check out who is exhibiting and find their booth on a map• Create a personal schedule• Message other attendees• Access other meeting information

The Mobile App is supported by Astellas Pharma US, Inc.

Name BadgesParticipant name badges must be displayed for admittance to all BMT Tandem Meetings scientific sessions, exhibits, meals and social events. For security reasons, name badges will be checked for admittance to all events and sessions.

Lost badges will be replaced for a charge of $5.

Physician Payments Sunshine ActBMT Tandem Meetings and the Medical College of Wisconsin (our CME sponsor) is committed to supporting full compliance with the Physician Payment Sunshine Act and strives toward full transparency with collaborators, governing bodies and our learners. Attendance may be tracked at mealtime sessions and poster sessions to report indirect transfers for value provided by a manufacturer to the Centers of Medicare and Medicaid Services in accordance with the Physician Payments Sunshine Act.

PostersTwo Poster Sessions will be held in Florida Hall B of the Gaylord Palms Convention Center. Session I is Wednesday, February 22 from 6:45 pm to 7:45 pm. Session II is Saturday, February 25 from 6:45 pm to 7:45 pm.

GE

NE

RA

L IN

FO

RM

AT

ION

9

RecordingsProfessional recordings are available for most plenary and concurrent scientific sessions, as well as parallel conferences. Each recording will be available in either MP3 or MP4 file format in the weeks following the conclusion of the BMT Tandem Meetings. They will be accessible through the online web program.

All available recordings will be made available to registered attendees for a $15 flat rate. This content is also offered to non-attendees: $25 for each MP3 audio download and MP4 audio with synchronized PowerPoint visuals.

Research Statistics ConsultationCIBMTR PhD biostatisticians are available to provide one-on-one consultation on current and planned research projects. No appointment is necessary between 10:30 am and Noon on Thursday and Friday in Room Sarasota 1, Level 2 to consult on study design, sample size, and power calculations.

Speaker Ready RoomThe Speaker Ready Room is located in Tampa 3, Level 2 at the Gaylord Palms Convention Center. The Speaker Ready Room hours are: Monday, February 20, 5:00 pm – 8:00 pm; Tuesday, February 21 through Saturday, February 25, 6:00 am – 6:00 pm; and Sunday, February 26, 6:00 am – 12:30 pm. Other availability is by appointment.

Wi-FiComplimentary Wi-Fi access is available in all BMT Tandem Meeting rooms at the Gaylord Palms Convention Center. Network Name: BMTTANDEM; Password: BMT2017!

Wi-Fi is available thanks to support from Novartis Pharmaceuticals Corporation.

10

Product TheatersBMT Tandem Meetings registered attendees are invited to participate in Product Theater presentations. These presentations are not sponsored or endorsed by the BMT Tandem Meetings. Product Theater sessions are considered promotional, and continuing education credits will not be offered.

Wednesday, February 22 1:30 pm – 2:30 pm Kite Pharma Product Theater: CAR-T Therapy in B-Cell Malignancies . . . . . Sun C

1:30 pm – 2:30 pm Cerus Corporation Product Theater: Mitigating Risks of Transfusion-Transmitted Infection and Transfusion-Associated GVHD with Pathogen-Reduced Blood Components . . Sun D

Thursday, February 23

1:30 pm – 2:30 pm Astellas Product Theater: Invasive Aspergillosis: Risk Factors, Diagnosis, and Overview of CRESEMBA® (isavuconazonium sulfate) Treatment with Case Presentation . . . . . . . . . . . . . . . . . . . . . . . . . Sun C

Friday, February 24 1:30 pm – 2:30 pm Jazz Pharmaceuticals Product Theater: Rising to the Challenge of VOD: Advances in the Treatment of Post HCT Patients . . . . . . Sun C1:30 pm – 2:30 pm Merck Product Theater: Importance of Antifungal Prophylaxis . . . . . . . Sun D

Saturday, February 25 1:30 pm – 2:30 pm Sanofi Product Theater: Barriers to HCT: Disparities in Multiple

Myeloma . . . . . . . . . . . . . . . . . . . . . . . . Sun C

1:30 pm – 2:30 pm Miltenyi Biotec Product Theater: Cellular Therapy: Established Strategies and Future Visions . . . . . . . . . . . . . . . . . . . . . . . . Sun D

CO

RP

OR

AT

ES

UP

PO

RT

11

Corporate SupportWe are grateful for the support of our corporate partners.

Platinum – $200,000Astellas Pharma US, Inc.

Incyte CorporationJazz Pharmaceuticals, Inc.

Pharmacyclics, LLCSanofi GenzymeSeattle Genetics

Gold – $100,000Actinium Pharmaceuticals, Inc.

Celgene CorporationKite Pharma, Inc.

Merck & Co. Novartis Pharmaceuticals Corporation

Silver – $50,000Janssen Biotech, Inc.

Millennium, the Takeda Oncology Co.Shire

Bronze – $10,000Cerus Corporation

Chimerix, Inc.Gilead Sciences, Inc.

HistoGeneticsKaryopharm Therapeutics, Inc.

Miltenyi Biotec, GmbH

12

Actinium Pharmaceuticals, Inc. – $155,625 an educational grant . . . and support for the Saturday breakfast symposium on “Updates on Hematologic Malignancies: New, Targeted Conditioning Regimens”.

Astellas Pharma US, Inc. – $204,000 an educational grant . . . and support for a Product Theater … Mobile App . . . Pocket Schedule . . . Infection and Immune Reconstitution Working Committee Meeting . . . and partial support for the Wednesday luncheon symposium on “Preventing and Managing Cytomegalovirus and Invasive Fungal Infection after Hematopoietic Stem Cell Transplantation: Key Questions, Expert Answers”.

Celgene Corporation – $173,915 an educational grant . . . and support for the Abstract Book . . . and partial support for the Thursday breakfast symposium on “Autologous Transplant in the Area of Novel Therapy in Myeloma”.

Cerus Corporation – $35,000 support for a Product Theater.

Chimerix, Inc. – $20,000 an educational grant . . . and support of the BMT Pharmacists Conference.

Gilead Sciences, Inc. – $15,000 support for the Graft-Versus-Host Disease Working Committee Meeting … and for the Notepad.

HistoGenetics – $45,000 support for the Registration Tote Bags.

Incyte Corporation – $450,731 an educational grant … and support for the Friday breakfast symposium on“Maximizing Patient Outcomes in Myelofibrosis: Stem Cell Transplantation in the JAK Inhibitor Era” . . . and partial support for the Saturday luncheon symposium on “Emerging Approaches to Target the Immunologic Chaos of Graft-Versus-Host Disease”.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. – $87,000 an educational grant . . . and partial support for the Thursday breakfast symposium on “Autologous Transplant in the Area of Novel Therapy in Myeloma”.

Jazz Pharmaceuticals, Inc. – $472,580 an educational grant . . . and support for a Product Theater … and for the Friday luncheon symposium on “Maximizing Outcomes with Allogeneic HCT in AML: Insight on the Impact of Novel Therapy”.

Karyopharm Therapeutics, Inc. – $29,750 an educational grant . . . and partial support for the Thursday breakfast symposium on “Autologous Transplant in the Area of Novel Therapy in Myeloma”.

13

CO

RP

OR

AT

ES

UP

PO

RT

Kite Pharma, Inc. – $135,000 an educational grant . . . and support for a Product Theater . . . and partial support for the Friday breakfast symposium on “Utilizing CAR T-Cells for Hematologic Malignancies in the Transplant Setting”.

Merck & Co. – $178,915 an educational grant . . . and support for a Product Theater . . . and partial support for the Wednesday luncheon symposium on “Preventing and Managing Cytomegalovirus and Invasive Fungal Infection after Hematopoietic Stem Cell Transplantation: Key Questions, Expert Answers”.

Millennium, the Takeda Oncology Co. – $60,000 an educational grant . . . and partial support for the Thursday breakfast symposium on “Autologous Transplant in the Area of Novel Therapy in Myeloma”.

Miltenyi Biotec, GmbH – $35,000 support for a Product Theater.

Novartis Pharmaceuticals Corporation – $105,000 an educational grant . . . and partial support for the Friday breakfast symposium on “Utilizing CAR T-Cells for Hematologic Malignancies in the Transplant Setting” . . . and support for Wi-Fi in all BMT Tandem Meeting rooms.

Pharmacyclics, LLC – $225,732 an educational grant . . . and partial support for the Saturday luncheon symposium on “Emerging Approaches to Target the Immunologic Chaos of Graft-Versus-Host Disease” . . . and support of the BMT Pharmacists Conference.

Sanofi Genzyme – $320,000 support for the Program Guide . . . support for the Saturday breakfast symposium on “Optimal Use of Stem Cell Mobilization in Patients with Hematologic Malignancies” . . . the Charging Lounge . . . and a Product Theater.

Seattle Genetics, Inc. – $250,000 an educational grant . . . and support for the Thursday luncheon symposium on “Making the Most of New Options in Hodgkin Lymphoma: Autologous Transplant in the Era of Novel Therapeutics”.

Shire – $75,000 an educational grant . . . and partial support for the Wednesday luncheon symposium on “Preventing and Managing Cytomegalovirus and Invasive Fungal Infection after Hematopoietic Stem Cell Transplantation: Key Questions, Expert Answers”.

With increasing demand for transparency regarding commercial supporters for accredited events, our accrediting bodies have asked that we include the amount of all support provided to the 2017 BMT Tandem Meetings as of January 13, 2017. This does not include fees received for promotional exhibits.

14

ASBMT Leadership 2016-2017ASBMT Executive Committee

President Christopher Bredeson, MD, MSc

President-Elect Krishna V. Komanduri, MD

Vice President John DiPersio, MD, PhD

Immediate-Past President Effie W. Petersdorf, MD

Secretary Juliet N. Barker, MBBS

Treasurer Corey S. Cutler, MD, MPH

Directors H. Joachim Deeg, MD Colleen Delaney, MD James Gajewski, MD Margaret L. MacMillan, MD, MSc Navneet S. Majhail, MD, MS Joseph McGuirk, DO Richard A. Nash, MD Pavan Reddy, MD Patrick J. Stiff, MD

Editor-in-Chief Biology of Blood and Marrow Transplantation Robert Korngold, PhD

Chair, Annual Meeting Scientific Program Committee Marcel R.M. van den Brink, MD, PhD

Executive Director Kenneth J. Luurs, MBA, CAE

Executive Office 85 West Algonquin Road, Suite 550 Arlington Heights, IL 60005 Telephone: (847) 427-0224 Fax: (847) 427-9656 Email: [email protected]

15

CIB

MT

RL

EA

DE

RS

HIP

CIBMTR Leadership 2016-2017CIBMTR Executive Committee

Chair Paul J. Martin, MD

Chair-Elect Robert J. Soiffer, MD

Vice-Chair for North America Paul Carpenter, MD

Vice-Chair for Central and South America Nelson Hamerschlak, MD, PhD

Vice-Chair for Europe Charles Craddock, MD, PhD

Vice-Chair for Asia/Australia/Africa Mahmoud Aljurf, MD, MPH

Patient/Family Representatives Jeff Haertling Maureen Beaman, MBA

Donor Center Representative Jason Gangewere

Collection Center Representative Yvonne Ybarra

Business Representative Theresa Franco, BSN, MSN

Chief Scientific Director Mary M. Horowitz, MD, MS

Executive Director Jeffrey W. Chell, MD

Associate Scientific Director Dennis L. Confer, MD

Chief Statistical Director Mei-Jie Zhang, PhD

Senior Research Advisor Daniel J. Weisdorf, MD

AS

BM

TL

EA

DE

RS

HIP

16

Senior Scientific Directors Linda J. Burns, MD Mary Eapen, MD, MS Marcelo C. Pasquini, MD, MS J. Douglas Rizzo, MD, MS Bronwen E. Shaw, MD, PhD

Scientific Directors Mukta Arora, MD, MS Anita D’Souza, MD, MS Mehdi Hamadani, MD Parameswaran N. Hari, MD, MS Stephanie J. Lee, MD, MPH Navneet S. Majhail, MD, MS Marcie L. Riches, MD, MS Wael Saber, MD, MS Stephen R. Spellman, MBS

Vice President, CIBMTR Minneapolis Roberta J. King, MPH

CIBMTR Administrator, CIBMTR Milwaukee Patricia Steinert, PhD, MBA

CIBMTR BMT Tandem Meetings Staff

Meetings Manager Tia Houseman

Director of Advancement Sherry Fisher

CIBMTR Program Coordinators Maira Brey Maggie Simaytis

CIBMTR is headquartered at two locations:

Milwaukee Campus at the Medical College of Wisconsin Clinical Cancer Center 9200 West Wisconsin Avenue, Suite C5500 Milwaukee, WI 53226 Telephone: (414) 805-0700

Minneapolis Campus at the Be The Match Coordinating Center 500 North 5th Street Minneapolis, MN 55401 Telephone: (612) 627-5800

17

TR

AV

EL

GR

AN

T R

EC

IPIE

NT

S

ASBMT Travel Grant RecipientsThe following hematology and oncology Fellows received travel grants from ASBMT to attend the 2017 BMT Tandem Meetings:

Brandon Blue, MD . . . . . . . . . . . . . . . . . . . . . St. Louis, MO

Michael Chargualaf, PharmD . . . . . . . . . . Chapel Hill, NC

Hannah Choe, MD . . . . . . . . . . . . . . . . . . . . . New York, NY

Coco deKoning. PhD . . . . . . . . . . . . .Utrecht, Netherlands

Najla El Jurdi, MD . . . . . . . . . . . . . . . . . . . . .Cleveland, OH

Jessica El-Asmar, MD . . . . . . . . . . . . . . . . . .Cleveland, OH

Narendranath Epperla, MD . . . . . . . . . . . . . Milwaukee, WI

Nicholas Gloude, MD . . . . . . . . . . . . . . . . . Cincinnati, OH

Brian Greenwell, MD . . . . . . . . . . . . . . . . . . . . Atlanta, GA

Ashish Gupta, MBBS, MPH, FAAP . . . . . . .Cleveland, OH

Patrick Hagen, MD, MPH . . . . . . . . . . . . . . . Maywood, IL

Mary Christa Krupski, DO . . . . . . . . . . . . . Cincinnati, OH

Hannah Major-Monfried . . . . . . . . . . . . . . . . New York, NY

Samip Master, MBBS . . . . . . . . . . . . . . . . . . .Shreveport, LA

Regina Myers, MD . . . . . . . . . . . . . . . . . . . .Philadelphia, PA

Ioannis Politikos, MD . . . . . . . . . . . . . . . . . . New York, NY

Praveen Ramakrishnan Geethakumari, MD . . . . . . . . . . . . . . . . . .Philadelphia, PA

Tahereh Rostami, MD . . . . . . . . . . . . . . . . . . . . Tehran, Iran

Seth Rotz, MD . . . . . . . . . . . . . . . . . . . . . . . Cincinnati, OH

Lyndsey Runaas, MD . . . . . . . . . . . . . . . . . . . . .Ypsilanti, MI

Mithun Shah, MD, PhD . . . . . . . . . . . . . . . . . Houston, TX

Akshay Sharma, MBBS . . . . . . . . . . . . . . . . . Memphis, TN

Tamna Wangjam, MD . . . . . . . . . . . . . . . . San Antonio, TX

18

Pre-ConferenCe Monday, February 20

MONDAY CONVENTION SERVICES:

5:00 pm – 8:00 pm Speaker Ready Room Tampa 3

5:00 pm – 8:00 pm Registration Open Exhibit Hall Lobby

MONDAY COMMITTEE MEETINGS:By Invitation

7:00 am – 5:00 pm FACT Standards Kick-Off MeetingEmerald 1

Tuesday, February 21

TUESDAY CONVENTION SERVICES:

6:00 am – 6:00 pm Speaker Ready Room Tampa 3

7:00 am – 6:00 pm Internet Access Center and Charging Lounge City Hall Lobby

7:00 am – 6:00 pm Registration Open Exhibit Hall Lobby

TUESDAY EXHIBITS: 10:00 am – 5:00 pm Exhibit Move-In Exhibit Hall F

19

PR

E-C

ON

FE

RE

NC

E

19

TUESDAY COMMITTEE MEETINGS:By Invitation

8:30 am – 5:00 pm BMT CTN Steering Committee Meeting Osceola C

6:00 pm – 10:00 pm FACT Board of Directors Meeting Daytona 1-2

TUESDAY PERIPHERAL CONFERENCES:

7:00 am – 5:00 pm FACT Cellular Therapy Inspection and Accreditation Workshop Applicant Track Tallahassee 1-3 Separate Registration Required. Contact FACT at [email protected] or call (402) 559-1950.

7:00 am – 5:00 pm FACT Cellular Therapy Inspection and Accreditation Workshop Inspector Track Sanibel 1-3 Separate Registration Required. Contact FACT at [email protected] or call (402) 559-1950.

7:30 am – 6:30 pm Clinical Research Professionals/Data Management (CRP/DM) Conference Osceola D See page 77 for agenda

8:00 am – Noon FACT Cellular Therapy Leadership Course 101 Miami 1 Separate Registration Required. Contact FACT at [email protected] or call (402) 559-1950.

1:00 pm – 5:00 pm FACT Advanced Cellular Therapy Leadership Course 201 Miami 1 Separate Registration Required. Contact FACT at [email protected] or call (402) 559-1950.

2020

Wednesday, February 22

WEDNESDAY CONVENTION SERVICES:



7:00 am – 6:00 pm Registration Open Exhibit Hall Lobby

WEDNESDAY EXHIBITS:

7:00 am – 2:00 pm Exhibits Open Exhibit Hall F

9:00 am – 5:00 pm BMT Tandem Poster Session I Set-Up and Preview Florida Hall B

6:45 pm – 7:45 pm BMT Tandem Poster Session I – Meet the Authors Florida Hall B

WEDNESDAY COMMITTEE MEETINGS:Open to All Attendees

7:00 am – 8:30 am Radiation Injury Treatment Network (RITN) Annual Update Sanibel 1-3

7:00 am – 5:00 pm FACT ASBMT Quality Boot Camp Miami 1-3 Separate Registration Required. Contact FACT at [email protected] or call (402) 559-1950.

10:00 am – 11:00 am ASBMT Introduction/Orientation for Fellows-in-Training Sanibel 1-3

2121

WEDNESDAY COMMITTEE MEETINGS:Open to All Attendees

12:15 pm – 2:15 pm CIBMTR Working Committee Meeting: Plasma Cell Disorders and Adult Solid Tumors Naples 1-3

12:15 pm – 4:45 pm CIBMTR Working Committee Meeting: Immunobiology Osceola 1-3

2:45 pm – 4:45 pm CIBMTR Working Committee Meeting: Late Effects and Quality of Life Naples 1-3

2:45 pm – 4:45 pm CIBMTR Working Committee Meeting: Primary Immune Deficiencies, Inborn Errors of Metabolism and Other Non-Malignant Marrow Disorders Osceola 4-6

5:00 pm – 6:30 pm Cell Therapy Registry Pilot Center Update St. George #108

5:00 pm – 7:00 pm FACT Global Affairs: Special Session for International Delegates Captiva 1-2

WEDNESDAY COMMITTEE MEETINGS:By Invitation

7:00 am – 8:00 am ASBMT Committee on Cellular Therapy St. George #112

7:00 am – 8:30 am Transplant Late Effects in Children (TLEC) Investigators Meeting Orange Blossom Ballroom

7:30 am – 8:30 am ASBMT Committee on RFI St. George #104

WE

DN

ES

DA

Y

2222

WEDNESDAY COMMITTEE MEETINGS:By Invitation

10:30 am – Noon FACT Clinical Outcomes Committee Meeting Daytona 1-2

Noon – 1:00 pm FACT Consultants Meeting Daytona 1-2

12:15 pm – 4:15 pm CIBMTR Advisory Committee Meeting Osceola C

1:00 – 2:00 pm FACT Consultants Board of Directors Meeting Daytona 1-2

5:00 pm – 6:30 pm CRP/DM Conference Planning Meeting for 2018 Sun 2

6:45 pm – 7:45 pm ASBMT Committee on Practice Guidelines St. George #112

6:45 pm – 8:00 pm FACT Web Oversight Committee Meeting Daytona 1-2

6:45 pm – 8:45 pm BMT CTN Myeloma Intergroup Meeting Tallahassee 1-3

7:00 pm – 9:00 pm NMDP Transplant Center Networking Reception – Open to NMDP/Be The Match Network Transplant Centers Only St. Augustine: Castillo de San Marcos Fort – Lower Level

WE

DN

ES

DA

Y

2323

WEDNESDAY PERIPHERAL CONFERENCES:

7:00 am – 8:15 am BMT CTN Investigators Meeting Sun B See page 81 for agenda

7:00 am – 5:30 pm Beyond Fundamentals of HCT Tallahassee 1-3 Separate Registration Required.

8:00 am – 10:00 am Introduction to the FACT Accreditation Portal Daytona 1-2 Separate Registration Required. Contact FACT at [email protected] or call (402) 559-1950.

8:30 am – 4:30 pm BMT CTN Coordinators Meeting Sun A See page 82 for agenda

8:30 am – 4:45 pm Clinical Research Professionals/ Data Management Conference Osceola B See page 78 for agenda

2:30 pm – 4:30 pm Introduction to the FACT Accreditation Portal Daytona 1-2 Separate Registration Required. Contact FACT at [email protected] or call (402) 559-1950.

2424

BREAKFAST OPTIONS

6:30 am – 8:15 am – Continental Breakfast Buffet Exhibit Hall F

7:00 am – 8:15 am BMT CTN Investigators Meeting The BMT CTN Investigators Meeting is for investigators and clinic and research staff involved in BMT CTN studies. Physicians at centers interested in becoming involved in the BMT CTN are also welcome to attend.

Sun B

7:00 am – 7:10 am Welcome Address


7:10 am – 7:30 am BMT CTN 0702 STaMINA Primary Results

Marcelo C. Pasquini, MD, MS

7:30 am – 7:45 am BMT CTN 1506 FLT3+ AML Maintenance Therapy

Yi-Bin Chen, MD

7:45 am – 8:00 am BMT CTN 0201 BM Versus PB Five-Year

Follow-Up Results Stephanie J. Lee, MD, MPH

8:00 am – 8:15 am Risk Stratified Trials in GVHD

Amin M. Alousi, MD

8:15 am – 8:30 am Opening Session: Welcome to the 2017 BMT Tandem Meetings Florida Hall E

Conference Co-Chairs: Marcel R.M. van den Brink, MD, PhD and David I. Marks, MBBS, PhD

WE

DN

ES

DA

Y

2525

SCIENTIFIC PLENARY SESSION

8:30 am – 10:00 am The Future of BMT “Immunotherapy of Cancer” Florida Hall E Chair: Ann M. Leen, PhD

Personalized Cancer Vaccines for Hematologic Malignancies

David E. Avigan, MD

Adoptively Transferred Tumor-Specific T-Cells Ann M. Leen, PhD

Targeting Personal Neoantigens through Cancer Vaccines

Catherine Wu, MD

10:00 am – 10:30 am – BMT Tandem Morning Break

CONCURRENT SCIENTIFIC SESSIONS

10:30 am – Noon NMDP Session: The Value of Emerging Cellular Therapies Florida Hall E Co-Chairs: Michael Boo, JD and Kent H. Walters, MBA

Industry Perspective on Valuing New Technologies Laurel Todd, MBA

Determining the Value of Cell Therapies through Health Services Research

Linda J. Burns, MD

Cell Therapy Reimbursement: The Good, the Bad, the Ugly

Stephanie A. Farnia, MPH

10:30 am – Noon Long-Term Survivorship after HCT: Roadmap for Research and Care Florida Hall D Chair: Minoo Battiwalla, MD, MS

The Potentially Lethal Late Effects Minoo Battiwalla, MD, MS

Patient-Reported Concerns: Psychological and Social Impact

André Tichelli, MD

HCT Survivorship: Research Methods and Care Delivery

Navneet S. Majhail, MD, MS

2626

10:30 am – Noon Primer on New Multiscale Biology/Immunology for Transplanters Florida Hall C Chair: Robert Negrin, MD

Modeling Organism-Wide Immunity in Health and Cancer

Matthew Spitzer, PhD

Immunobiology of Tolerance Induction with Low-Dose Interleukin-2

John Koreth, MBBS, DPhil

High Throughput Sequencing to Track T-Cell Cloning Units of Disease in Hematopoietic Cell Transplantation

Everett Meyer, MD, PhD

LUNCH OPTIONS

Noon – 1:15 pm – BMT Tandem Buffet Exhibit Hall F

BMT TANDEM LUNCHEON SYMPOSIUM:

12:30 pm – 1:30 pm Preventing and Managing Cytomegalovirus and Invasive Fungal Infection after Hematopoietic Stem Cell Transplantation: Key Questions, Expert Answers Florida Hall E

Introduction and Key Questions on the Modern Prevention and Treatment of CMV and Invasive Fungal Infection in the HCT Setting

Dimitrios P. Kontoyiannis, MD

Advances in Treatment and Prevention of CMV Disease in HCT Recipients

Michael J. Boeckh, MD

Invasive Fungal Infections in HCT Recipients: Evidence-Based Perspectives on Prevention and Treatment

Dimitrios P. Kontoyiannis, MD

Q&A and Concluding Remarks Dimitrios P. Kontoyiannis, MD

This activity is supported by independent educational grants from Astellas, Merck & Co., Inc., and Shire.

WE

DN

ES

DA

Y

2727

MEET-THE-PROFESSOR SESSIONS:

Meet-the-Professor luncheon tickets are $35, available for purchase at the BMT Tandem Meetings Registration Desk and subject to availability.

12:15 pm – 1:30 pm Evolution and History of HCT Sun 1

Richard J. O'Reilly, MD and Rainer Storb, MD

12:15 pm – 1:30 pm Cord Blood Transplant Sun 2

Juliet N. Barker, MBBS

CONCURRENT ORAL ABSTRACT SESSIONS

4:45 pm – 6:45 pm Oral Abstracts – Session A: Late Effects, Supportive Care and Quality of Life Florida Hall E Moderators: John R. Wingard, MD and

Linda J. Burns, MD

Inpatient Integrated Palliative and Transplant Care Improves Caregiver Outcomes of Patients Hospitalized for Hematopoietic Stem Cell Transplantation

Areej R. El-Jawahri, MD

PROMIS and SF36 Patient Reported Outcome Scores are Strongly Correlated in Transplant Survivors

Bronwen E. Shaw, MD, PhD

Association of Socioeconomic Status with Chronic Graft-Versus-Host Disease Outcomes

Betty Ky Hamilton, MD

Risks of New Myeloid Neoplasms after Autologous Transplant for Plasma Cell Myeloma and Lymphomas: Effects of Drug and Ionizing Radiation Exposures

Shahrukh K. Hashmi, MD, MPH

Patient-Reported Outcomes Associated with Chronic GVHD

Stephanie J. Lee, MD, MPH

2828

Long-Term Outcomes Among Two-Year Survivors of Autologous Hematopoietic Cell Transplant for Hodgkin and Diffuse Large B-Cell Lymphoma

Regina Myers, MD

Modifiable Barriers to Adherence to Recommended Health Care Guidelines in Hematopoietic Cell Transplantation Long-Term Survivors

Karen L. Syrjala, PhD

Correlates of Patient and Family Caregiver Anxiety and Depression Symptoms Prior to Allogeneic Hematopoietic Cell Transplantation

Donna M. Posluszny, PhD

4:45 pm – 6:45 pm Oral Abstracts – Session B: Leukemia and Infection Florida Hall D Moderators: Navneet S. Majhail, MD, MS and

John A. Snowden, MD

Human Rhinovirus Infections in Hematopoietic Cell Transplant Recipients: Factors Determining Progression to Lower Tract Disease

Alpana Waghmare, MD

Early Post-Transplant Viral Infections and the Incidence of Acute and Chronic Noninfectious Pulmonary Complications following Hematopoietic Stem Cell Transplantation

Xiaofeng Zhou, PhD

ABO Mismatching and Haploidentical Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia – a Report from the ALWP of the EBMT

Bipin N. Savani, MD

Outcomes of Allogeneic Hematopoietic Cell Transplantation for AML with Complex Karyotypes: A Retrospective Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and MD Anderson Cancer Center

Stefan O. Ciurea, MD

WE

DN

ES

DA

Y

2929

Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 with Untreated Secondary Acute Myeloid Leukemia Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Jeffrey E. Lancet, MD

Survival Outcomes Based on Treatment Modality in Acute Lymphoblastic Leukemia: NCDB Analysis

Samip Master, MD

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients

Mithun Vinod Shah, MD, PhD

Infusion of Donor Lymphocytes Specifically Directed to Multiple Tumor Antigens for the Treatment of High-Risk Patients after HCT

Kirsten M. Williams, MD

4:45 pm – 6:45 pm Oral Abstracts – Session C: Lymphoma and Myeloma and Clinical Cellular Therapy Florida Hall C Moderators: Hillard M. Lazarus, MD and

Thomas C. Shea, MD

Outcomes in Hodgkin Lymphoma Patients following Allogeneic Transplant after Post-Autologous Transplant Consolidation Therapy with Brentuximab Vedotin: Results of an Exploratory Analysis in the AETHERA Trial

Amanda Cashen, MD

Autologous Transplantation is Associated with Improved Overall Survival in Follicular Lymphoma Patients Experiencing Early Therapy Failure after Frontline Chemo-Immunotherapy: A National Lymphocare Study & CIBMTR Analysis

Carla Casulo

Rituximab Versus Non-Rituximab Containing Reduced Intensity Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in B-Cell Non-Hodgkin Lymphomas: A CIBMTR Analysis

Narendranath Epperla, MD

3030

Post-Relapse Survival in Lymphoma Patients after Experiencing Therapy Failure following an Allogeneic Hematopoietic Cell Transplantation

Narendranath Epperla, MD

Allogeneic Hematopoietic Cell Transplantation for Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A CIBMTR Analysis

Abraham S. Kanate, MD

Adoptive Transfer of Multi-Tumor Antigen Specific T-Cells as Treatment for Patients with Multiple Myeloma

Premal Lulla, MD

Safety and Efficacy of Donor T-Cells Engineered with Herpes Simplex Virus Thymidine-Kinase Suicide Gene Given after T-Cell Depleted Haploidentical Hematopoietic Transplantation: Results of a 14-Year Follow-Up in 45 Patients

Fabio Ciceri, MD

Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor-T-Cells in Patients with B-Cell Non-Hodgkin Lymphoma: Reversal of Toxicity from Tonic Signaling

Carlos A. Ramos, MD

BMT TANDEM POSTER SESSION I

6:45 pm – 7:45 pm BMT Tandem Poster Session I – Meet the Authors Florida Hall B

Session I Posters will remain for viewing until 5:00 pm on Thursday.

3131


THURSDAY CONVENTION SERVICES:



7:00 am – 6:00 pm Registration Open Exhibit Hall Lobby F

THURSDAY EXHIBITS: 7:00 am – 2:00 pm Exhibits Open Exhibit Hall F

9:00 am – 5:00 pm BMT Tandem Poster Session I ViewingFlorida Hall B Session I Posters must be removed by 6:00 pm on Thursday.

6:15 pm – 7:15 pm Welcome ReceptionExhibit Hall F Kick off the 2017 BMT Tandem Meetings by attending the Welcome Reception in Exhibit Hall F. Enjoy complimentary appetizers and beverages as you network with colleagues and our industry partners.

THURSDAY COMMITTEE MEETINGS:Open to All Attendees

7:00 am – 8:15 am Orientation to CIBMTR/BMT CTN Naples 1-3

10:30 am – Noon Statistical Consulting with CIBMTR PhD Biostatisticians Sarasota 1

TH

UR

SD

AY

3232

THURSDAY COMMITTEE MEETINGS:Open to All Attendees

12:15 pm – 2:15 pm CIBMTR Working Committee Meeting: Acute Leukemia Osceola 4-6

12:15 pm – 2:15 pm CIBMTR Working Committee Meeting: Autoimmune Diseases and Cellular Therapies Osceola 1-3

1:00 pm – 3:30 pm International Data Managers Open Forum St. George #108

2:45 pm – 4:45 pm CIBMTR Working Committee Meeting: Graft Sources and Manipulation Osceola 4-6

2:45 pm – 4:45 pm CIBMTR Working Committee Meeting: Lymphoma Osceola 1-3

THURSDAY COMMITTEE MEETINGS:By Invitation

7:00 am – 8:30 am ASBMT Committee on Education St. George #104

7:00 am – 8:30 am RCI BMT Clinical Trials Advisory Committee (CTAC) Meeting Orange Blossom Ballroom

7:30 am – 8:30 am ASBMT Palliative Care Special Interest Group St. George #112

8:30 am – 10:00 am BMT CTN Coordinators and Investigators Planning Meeting for 2018 Sun 1

TH

UR

SD

AY

3333


9:00 am – 10:30 am FACT CIBMTR Data Audit Meeting Daytona 1-2

11:00 am – Noon FACT CAR T-Cell Task Force Meeting Daytona 1-2

Noon – 1:00 pm FACT Regenerative Medicine Task Force Meeting Daytona 1-2

Noon – 1:30 pm ASBMT Past President’s Luncheon St. George #112

12:15 pm – 1:15 pm ASBMT Committee on Quality Outcomes Emerald 1

12:30 pm – 2:15 pm ASBMT Survivorship Research and Special Interest Group Meeting Orange Blossom Ballroom

1:00 pm – 4:30 pm BMT Data Standards and Interoperability Sun 4-6

1:15 pm – 2:15 pm ASBMT Sub-Committee on Informatics Emerald 1

1:30 pm – 3:00 pm BBMT Editorial Board Meeting St. George #106

2:00 pm – 3:00 pm ASBMT Choosing Wisely Task Force Emerald 6

2:45 pm – 4:45 pm Patient-Centered Outcomes Research Institute Survivorship Care Plan (13-SCP) Study Meeting Orange Blossom Ballroom

4:30 pm – 5:30 pm ASBMT Corporate Council Reception Emerald Bay Plaza: Wedding Pavilion

34


4:45 pm – 6:15 pm CIBMTR Consumer Advocacy Committee Meeting Emerald 6

6:15 pm – 7:00 pm PBMTC Business Meeting and Reception Osceola A

THURSDAY PERIPHERAL CONFERENCES:

8:30 am – 5:30 pm Beyond Fundamentals of HCT Tallahassee 1-3 Separate Registration Required.

8:30 am – 5:15 pm Transplant Nursing Conference Osceola D See page 99 for agenda

8:30 am – 6:00 pm Administrative Directors Conference Sun A See page 87 for agenda

8:30 am – 7:00 pm Pediatric BMT Program Osceola AB See page 36 for agenda

9:00 am – 3:30 pm In-Depth Training for Clinical Research Professionals/Data Management Sanibel 1-3 See page 80 for agenda

1:00 pm – 3:00 pm and 3:00 pm – 5:00 pm Open to All Attendees Introduction to the FACT Accreditation Portal Day Two Daytona 1-2 Separate Registration Required. Contact FACT at [email protected] or call (402) 559-1950.

35

TH

UR

SD

AY

BREAKFAST OPTIONS


BMT TANDEM BREAKFAST SYMPOSIUM:

7:00 am – 8:00 am Autologous Transplants in the Area of Novel Therapy in Myeloma Florida Hall E

Welcome and Introduction Kenneth C. Anderson, MD

The Impact of Novel Therapies on Autologous HCT in Myeloma

Kenneth C. Anderson, MD

Selecting Optimal Treatment in Post-Transplant Relapsed Disease

Shaji Kumar, MD

Symposium Summary and Audience Q&A Panel

This activity is supported by educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Karyopharm Therapeutics and Takeda Oncology.

3636

Pediatric BMT Program

The Pediatric BMT Program, run in conjunction with the Pediatric Blood and Marrow Transplant Consortium (PBMTC), is a meeting for physicians, advanced practitioners, nurses, pharmacists, and other staff involved in caring for children undergoing BMT to learn about cutting-edge science and state-of-the-art advances in treatment related to these pediatric patients and the diseases for which they are being treated.

The Medical College of Wisconsin designates this live activity for a maximum of 8.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Thursday, February 23 Osceola AB


8:30 am – 10:00 am Faith-Based Practice: Rare Complications Post-Transplant Osceola C Chair: Rebecca A. Marsh, MD

Chimerism Rebecca A. Marsh, MD

Cytopenias Elie Haddad, MD, PhD

TMA after Stem Cell Transplantation: Crossroad between Our Beliefs and Science

Sonata Jodele, MD

10:00 am – 10:30 am – Break

PE

DIA

TR

IC B

MT

PR

OG

RA

M

3737

CONCURRENT PEDIATRIC SESSIONS

10:30 am – Noon My Sister's Keeper – Pediatric Donor Outcomes Osceola C Chair: Michael A. Pulsipher, MD

New Insights into Medical Aspects of the Pediatric Donor Experience

Michael A. Pulsipher, MD

Insights into the Pediatric Bone Marrow Donor Experience by Studying Quality of Life Measures

Galen E. Switzer, PhD

How Can Quality of Life Studies in Siblings of Children with Cancer Inform Our Understanding of Sibling Donor Quality of Life?

Cynthia A. Gerhardt, PhD

10:30 am – Noon New Kids on the Block – Potential New Targetable Pathways Osceola A Chair: Alex Huang, MD, PhD

New Roles for Notch Ligands and Fibroblastic Stromal Cells in GVHD

Ivan Maillard, MD, PhD

Cdk5 in Allogeneic T-Cell Activation John Letterio, MD

IL-27, a Cytokine to Enhance Treg Function to Treat GVHD

Booki Min, PhD

Noon – 12:15 pm – Pediatric BMT Quick Lunch Buffet

3838

12:15 pm – 1:15 pm Pediatric Lifetime Achievement Award Osceola C

Harnessing the Power of the Hematopoietic Stem Cell

John E. Wagner, MD

Dr. John Wagner is the ninth recipient of the Lifetime Achievement Award from the Pediatric Blood and Marrow Transplant Consortium (PBMTC). Dr. Wagner is being recognized for a career that exemplifies the mission of the PBMTC to support research and education to improve the availability, safety and efficacy of hematopoietic cell transplantation and other cellular therapeutics for children and adolescents.

Dr. Wagner is the Executive Medical Director for the BMT Program at the University of Minnesota Masonic Children’s Hospital and a Professor of Pediatrics at the University of Minnesota Medical School. He is internationally recognized as an expert in the field of stem cells and umbilical cord blood transplantation. He was the first to use umbilical cord blood to treat a child with leukemia in 1990. Dr. Wagner’s research has focused on the development of new treatment approaches for life-threatening diseases for which conventional treatments are unsatisfactory. He is recognized for pioneering the use of double umbilical cord blood transplantation in adults and embryo selection to insure an HLA-matched, healthy child (‘savior sibling’) for another child in need of transplant. He is a leader in the use of regulatory T-Cells to prevent rejection and Graft-Versus-Host Disease, expanded blood-forming stem cells to speed blood and marrow recovery, novel conditioning regimens to dramatically increase the chance of cure of patients with Fanconi anemia and bone marrow derived stem cells to repair the skin in severely affected children with Epidermolysis Bullosa. In addition to being a world-class researcher, physician, author and advisor, Dr. Wagner has made tremendous contributions to medical research by mentoring scientists and physicians who have become leaders in the field.

1:15 – 1:30 pm – Break

PE

DIA

TR

IC B

MT

PR

OG

RA

M

3939

CONCURRENT PEDIATRIC SESSIONS

1:30 pm – 3:00 pm Aplastic Anemia – Innovative Approaches Osceola CChair: Andrew C. Dietz, MD, MSCR

Alternative Treatment with Eltrombopag and Immunosuppression

Danielle Townsley, MD, MSc

Serotherapy in BMT for Severe Aplastic Anemia Paul Veys, MBBS

Evolving Transplant Stategies in Severe Aplastic Anemia

Andrew C. Dietz, MD, MSCR

1:30 pm – 3:00 pm TMI: Too Much Inflammation Osceola A Chair: Carl Allen, MD

HLH – New Definitions and New Therapies Carl Allen, MD

Obesity and Inflammation in HCT Lucie Turcotte, MD

Cytokine Release Syndrome in Cell Therapy David T. Teachey, MD

3:00 pm – 3:15 pm – Break

3:15 pm – 4:15 pm International Session: Check Please – Financial Aspects of Cellular Therapy Osceola CChair: Margaret L. MacMillan, MD, MSc

Canadian Perspective Christopher Bredeson, MD, MSc

U.S. Perspective Stephanie A. Farnia, MPH

4:15 pm – 6:15 pm Best Pediatric Abstracts Osceola CModerators: Carrie L. Kitko, MD and Terry Fry, MD

Augmentation of Allogenic Cord Blood Transplant-ation for Inherited Metabolic Diseases with CB-Derived Intrathecal Cellular Therapy, Duoc-01

Jessica Sun, MD

4040

Genotype, Phenotype and T-Cell Counts at One Year Predict Survival and Long-Term Immune Reconstitution after Transplantation in Severe Combined Immune Deficiency – the Primary Immune Deficiency Treatment Consortium

Elie Haddad

A Prospective Phase 2 Clinical Trial of KIR Mismatched Unrelated Donor Transplantation for Children and Young Adults with High-Risk AML: A Report of Children’s Oncology Group AAML05P1 Study

Stella M. Davies, MBBS, PhD

Donor Lymphocyte Infusion with Methotrexate to Speed Immune Recovery after CD34-Selected, T-Cell Depleted Haploidentical Donor Transplantation in Children

Andrew L. Gilman, MD

Radiation-Free Salvage Haploidentical HCT with Post-Tx Cy after Rejection/Graft Failure in Children with Non-Malignant Disorders

Michael H. Albert, MD

ROR1-Specific Chimeric Antigen Receptor NK Cell Immunotherapy for High-Risk Neuroblastomas and Sarcomas

Mitchell S. Cairo

CD38 Bright CD8+ TEM Cells Detected Prior to Acute GVHD are Activated, Cytotoxic, Proliferating, Trafficking Cells which are Not Viral Specific

Pooja Khandelwal, MD

Haematopoietic Cell Transplant in Pediatric Acute Myeloid Leukemia after Similar Upfront Therapy with AML-Nopho; A Comparison of Conditioning Regimens

Birgitta Versluys, MD

6:15 pm – 7:00 pm PBMTC Business Meeting and Reception Osceola A

4141

Thursday, February 23SCIENTIFIC PLENARY SESSION

8:30 am – 10:00 am Aging – Treating the Older Patient Florida Hall E Chair: Andrew S. Artz, MD, MS

The Biology of Frailty and Age-Related Vulnerability to Adverse Health Outcomes

Jeremy Walston, MD

The Older Myeloma Patient: Evaluating Aging and Understanding Fitness for Autografting

Ashley Rosko, MD

The Older AML Patient: Candidacy and Optimization for Allogeneic Transplant

Andrew S. Artz, MD, MS

10:00 am – 10:30 am – Break


10:30 am – Noon HaploBMT: A Primer for the Novice and an Update for the Experienced Florida Hall E Chair: Leo Luznik, MD

The Biology of PTCy: How it Allows Us to Cross the HLA Barrier

Christopher G. Kanakry, MD

Choosing a Donor Versus Choosing a Regimen – What Do We Know and What Do We Need to Know?

Richard J. Jones, MD

Relapse after HaploBMT Luca Vago, MD, PhD

TH

UR

SD

AY

4242

10:30 am – Noon Challenges to BMT in Older Patients: Myeloma, Lymphoma/CLL Florida Hall D Chair: Hermann Einsele, MD

Impact of Age and Disease Risk on Treatment Decisions in MDS H. Joachim Deeg, MD

Is Stem Cell Transplantation Still the Preferred Therapeutic Option for Eligible Patients with Multiple Myeloma? Hermann Einsele, MD

An Approach to Defining High-Risk Chronic Lymphocytic Leukemia Justifying Allogeneic Transplantation in the Era of Targeted Therapies Peter Dreger, MD, PhD

10:30 am – Noon HCT in Autoimmune Diseases Florida Hall C Chair: John A. Snowden, MD

Autologous HCT in Multiple Sclerosis John A. Snowden, MD

Autologous HCT in Connective Tissue Diseases: Clinical Results and Mechanisms Tobias Alexander, MD

Autologous HCT in Inflammatory Bowel Diseases Montserrat Rovira, MD, PhD

LUNCH OPTIONS

Noon – 1:15 pm – BMT Tandem Buffet Exhibit Hall F Refer to page 4 for a variety of lunch options.

4343



12:15 pm – 1:30 pm Unusual Lymphomas and the Role of Autografting and Allografting Sun 1 Timothy S. Fenske, MD, MS

12:15 pm – 1:30 pm Selecting an Alternative Donor Sun 2 Bronwen E. Shaw, MD, PhD


12:30 pm – 1:30 pm Making the Most of New Options in Hodgkin Lymphoma: Autologous Transplant in the Era of Novel Therapeutics Florida Hall E

Welcome and Introductions Anas Younes, MD

Autologous Transplant, Novel Therapies and the Current Hodgkin Lymphoma Paradigm

Robert Chen, MD

A Practical Look at Integrating New Therapy in the Post-HCT Setting

Anas Younes, MD

Key Takeaways and Audience Q&A Anas Younes, MD and Robert Chen, MD

This activity is supported by an educational grant from Seattle Genetics.

TH

UR

SD

AY

4444


4:45 pm – 6:15 pm Oral Abstracts – Session D: Clinical Cellular Therapy, Graft Processing and Immune Reconstitution Florida Hall E Moderators: Helen E. Heslop, MD and

John F. DiPersio, MD, PhD

TCRb Sequencing Demonstrates Polyclonality and Persistence of Virus-Specific T-Cell Therapy Michael Daniel Keller

Stem Cell-Like Memory T-Cells are a Principal Source for Rapid Repopulation of Immunodominant CMVpp65-Specific Central Memory and Effector Memory T-Cells Aisha Nasreen Hasan, MD

Prophylactic Donor Lymphocyte Infusion Prolongs Overall Survival after Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukaemia – Results from a Retrospective Matched Pair Analysis by the Acute Leukaemia Working Party Christoph Schmid, MD

Safety and Preliminary Efficacy of “Ready to Administer” Cytomegalovirus-Specific T-Cells for the Treatment of Patients with Refractory CMV Infection Ifigeneia Tzannou, MD

The Cost Effectiveness of Manufacturing Antigen-Specific T-Cells in an Academic GMP Facility Patrick J. Hanley

Clonal Deletion Plays a Major Role to Achieve Tolerance after Reduced Intensity Unrelated Donor Cord Blood Transplantation Paul Szabolcs, MD

4545

4:45 pm – 6:15 pm Oral Abstracts – Session E: Allogeneic Transplants Florida Hall D Moderators: Brenda M. Sandmaier, MD and

Rizwan Romee, MD

Optimizing Anti-Thymocyte Globulin Exposure to Improve Survival Chances after Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome Jaap-Jan Boelens, MD, PhD

A Prospective Observational Study to Evaluate a Cytomegalovirus-Specific Enzyme-Linked Immunospot Assay in Allogeneic Hematopoietic Cell Transplant Recipients: The REACT Study Roy F. Chemaly, MD, MPH

The Impact of Pre- and Week 4 Post-Transplant CMV-Specific Elispot Assay on CMV Reactivation and Survival in CMV-Seropositive Allogeneic Hematopoietic Cell Transplant Recipients Roy F. Chemaly, MD, MPH

Application of the CIBMTR Survival Outcomes Calculator to CD34-Selected Allogeneic HCT for Acute Leukemia and Myelodysplastic Syndrome Christina Cho, MD

Combining the Disease Risk Index and Hematopoietic Cell Transplantation Comorbidity Index Provides a Comprehensive Prognostic Model for CD34-Selected Allogeneic HCT Christina Cho, MD

Disease Characteristics and Overall Survival in Pediatric Patients with Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia after Stem Cell Transplantation Alessandro Crotta

TH

UR

SD

AY

4646

4:45 pm – 6:15 pm Oral Abstracts – Session F: Infectious Disease Florida Hall C Moderators: Michael J. Boeckh, MD and

Jose F. Camargo, MD

Outcomes after Allogeneic Hematopoietic Cell Transplantation with Donors or Recipients Harboring Inherited Chromosomally Integrated HHV-6 Joshua A. Hill, MD

Impact of Respiratory Virus Infection before Hematopoietic Cell Transplantation on Post-Transplant Outcomes in Adults in the PCR Era: Do Rhinovirus and Coronavirus Infections Matter? Yae-Jean Kim, MD, PhD

Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant or Solid Organ Transplant Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study Genovefa A. Papanicolaou, MD

Treatment of Adenovirus Infection in Allogeneic Hematopoietic Cell Transplant Patients with Brincidofovir: Final 36 Week Results from the Advise Trial Vinod K. Prasad, MD

Prospective Assessment of Diagnostic Infectious Disease Molecular PCR Testing with Early Fiberoptic Bronchoscopy in the Evaluation of New Pulmonary Infiltrates in Hematopoietic Stem Cell Transplantation and Acute Leukemia Patients Melissa Sanacore, PharmD

Administration of Banked, 3rd Party Multivirus-Specific T-Cells to Treat Drug-Refractory EBV, CMV, AdV, HHV6, and BKV Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients Ifigeneia Tzannou, MD

4747

Friday, February 24

FRIDAY CONVENTION SERVICES:




FRIDAY EXHIBITS:


9:00 am – 5:00 pm BMT Tandem Poster Session II Set-Up and Preview Florida Hall B

FRIDAY COMMITTEE MEETINGS:Open to All Attendees

7:00 am – 8:30 am ASBMT Infectious Disease Special Interest Group Meeting Sun 4-6

7:30 am – 8:30 am Improving Clinical Outcomes with FACT Accreditation Sanibel 1-3

10:30 am – Noon Statistical Consulting with CIBMTR PhD Biostatisticians Sarasota 1

12:15 pm – 2:15 pm CIBMTR Working Committee Meeting: Graft-Versus-Host Disease Osceola 4-6 Supported by a grant from Gilead Sciences, Inc.

FR

IDA

Y

4848

FRIDAY COMMITTEE MEETINGS:Open to All Attendees

12:15 pm – 2:15 pm CIBMTR Working Committee Meeting: Health Services and International Studies Osceola 1-3

12:15 pm – 2:15 pm CIBMTR Working Committee Meeting: Regimen-Related Toxicity Naples 1-3

4:00 pm – 5:00 pm Transplant Nursing Special Interest Group Steering Committee Meeting Osceola D

6:45 pm – 8:45 pm LABMT – Latin America Blood and Marrow Transplant Group Meeting Tallahassee 1-3

FRIDAY COMMITTEE MEETINGS:By Invitation

7:00 am – 8:30 am Pediatric BMT Program Planning Meeting for 2018 Sun 1

7:00 am – 8:30 am ASBMT/CIBMTR/NMDP Leadership Meeting St. George #106

7:00 am – 8:30 am Naïve T-Cell Depletion for Prevention of Chronic GVHD (NTCD) Investigators Meeting Orange Blossom Ballroom

10:30 am – 1:30 pm WBMT Board Meeting Miami 1-3

10:30 am – 2:30 pm ASBMT Board of Directors Meeting Orange Blossom Ballroom

4949

FRIDAY PERIPHERAL CONFERENCES:

8:15 am – 5:00 pm BMT Pharmacists ConferenceOsceola ASee page 95 for agenda

8:15 am – 5:30 pm BMT Clinical Education Conference (for NPs, PAs, Fellows and Junior Faculty) Osceola C See page 91 for agenda


8:30 am – 5:55 pm Administrative Directors Conference Sun A See page 89 for agenda

BREAKFAST OPTIONS



7:00 am – 8:00 am Maximizing Patient Outcomes in Myelofibrosis: Stem Cell Transplantation in the JAK Inhibitor Era Florida Hall D

Welcome and Introductions Nicolaus Kröger, MD

Where Does Allogeneic HCT Fit in the JAK Inhibitor Treatment Era?

Vikas Gupta, MD

Combinations for Potential Cures in MF: Integrating Transplant with JAK Inhibitors

Nicolaus Kröger, MD

Thoughts on Combined Modality Care in MF and Ask-the-Experts Q&A

Nicolaus Kröger, MD and Vikas Gupta, MD

This activity is supported by an educational grant from Incyte Corporation.

FR

IDA

Y

5050

BREAKFAST SYMPOSIUM:

7:00 am – 8:00 am Utilizing CAR T-Cells for Hematologic Malignancies in the Transplant Setting Florida Hall E

Introduction Stephan A. Grupp, MD, PhD

Update of Current Clinical Trials Using CAR T-Cells

Stephan A. Grupp, MD, PhD

CAR T-Cell Therapy for Hematological Malignancies Other than CD19

Helen E. Heslop, MD

Discussion/Q&A

This activity is supported by an educational grant from Kite Pharma, Inc. and Novartis Pharmaceuticals Corporation.


8:30 am – 10:00 am Acute GVHD Florida Hall E Chair: James Ferrara, MD, DSc

Antigen Presentation in Acute GVHD Motoko Koyama, MD, PhD

The Microbiome in Acute GVHD Ernst Holler, MD, PhD

Biomarkers in Acute GVHD James Ferrara, MD, DSc

10:00 am – 10:30 am – Break

5151


10:30 am – Noon Oral Abstracts – Session G: Palliative/Supportive Care/Nutrition and Quality and Value Florida Hall E Moderators: Natasha Kekre, MD, MPH and

Alan M. Hanash, MD, PhD

Randomized Trial of Inpatient Palliative Care Intervention for Patients Hospitalized for Hematopoietic Stem Cell Transplantation


Prediction of Opioid Requirement for Mucositis by Genotype in Children Undergoing Hematopoietic Cell Transplantation

M. Christa Krupski, DO, MPH

Increased Vitamin D Binding Protein Levels are Associated with Improved Overall Survival following Bone Marrow Transplant in Children

Nathan Luebbering, MS

Adipokine Concentrations and Adiposity in Hematopoietic Cell Transplant Survivors

Tyler G. Ketterl, MD

A Risk-Adapted Protocol of Prophylactic Zoledronic Acid Prevents Bone Mineral Density Loss Post-Allograft: Results of the ALLG BM07 Phase II Prospective Trial

Eric Wong

Understanding Physicians’ Perspectives about Translating Research into Clinical Practice: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Results

Nandita Khera, MD

FR

IDA

Y

5252

10:30 am – Noon Oral Abstracts – Session H: Pediatric Disorders Florida Hall C Moderators: Carrie L. Kitko, MD and

Margaret L. MacMillan, MD, MSc

Reduced Intensity Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease: Results of a Phase I Trial Allistair Abraham, MD

Incorporating Immunocytokine and Ex Vivo Expanded NK Cells to Improve Allogeneic Bone Marrow Transplant for Neuroblastoma Christian M. Capitini, MD

Challenges with Diagnosing Pulmonary Chronic GVHD in Children as per the 2014 National Institutes of Health Consensus Criteria: Applied Biomarkers of Late Effects/Pediatric Blood and Marrow Transplant Consortium 1202 Study Geoff D.E. Cuvelier, MD

Neurologic-Event-Free Survival: A New Endpoint for Severe Combined Immunodeficiency Patients Diagnosed by Newborn Screening and Treated with Hematopoietic Cell Transplantation Christopher C. Dvorak, MD

Haploidentical Hematopoietic Stem Cell Transplantation using Tcrαβ/CD19 Depleted Grafts in Children with High-Risk Leukemia Marta Gonzalez, MD, PhD

T-Cell Costimulation Blockade with Abatacept along with Pre-Transplantation Sirolimus and Post-Transplantation Cyclophosphamide Promotes Early Recovery of Tregs and Reduces Early Alloreactivity after Haploidentical PBSCT for Severe Aplastic Anemia Sarita Jaiswal, BSc, MD

5353

10:30 am – Noon Oral Abstracts – Session I: Autologous Transplants Florida Hall D Moderators: Sergio A. Giralt, MD and

Emma C. Morris, MD, PhD

A Phase 1/2 Trial of Carfilzomib + High-Dose Melphalan Conditioning for Auto-HCT followed by Carfilzomib Maintenance for Patients with Relapsed Multiple Myeloma

Luciano J. Costa, MD, PhD

High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma in First Complete Remission

Zachariah M. DeFilipp, MD

Trends in Survival Outcomes Among Patients Relapsing Early after Autologous Stem Cell Transplantation for Multiple Myeloma (CIBMTR Study # MM14-03)

Angela Dispenzieri, MD

Autologous Stem Cell Transplantation with Benda-CV in Non-Hodgkin and Hodgkin Lymphoma Patients

Gregorio Jaimovich

Infusion of Autograft Natural Killer Cells/CD14+HLA-DRDIM Myeloid-Derived Suppressor Cells Ratio Predicts Survival in Non-Hodgkin Lymphoma Undergoing Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

Ankit J. Kansagra, MD

Total Marrow Irradiation Combined with High-Dose Melphalan for Patients with Relapsed/ Refractory Multiple Myeloma: A Phase 1 Study

Pritesh Rajni Patel, MB, ChB

LUNCH OPTIONS

Noon – 1:15 pm – BMT Tandem Buffet Exhibit Hall F Refer to page 4 for a variety of lunch options.

FR

IDA

Y

5454



12:15 pm – 1:30 pm All Things HLH Sun 1

Rebecca A. Marsh, MD

12:15 pm – 1:30 pm Special Considerations in HCT for Patients with Sickle Cell Disease Sun 2

Nicolas Novitzky, MD, PhD


12:30 pm – 1:30 pm Maximizing Outcomes with Allogeneic HCT in AML: Insight on the Impact of Novel Therapy Florida Hall E

Welcome and Introduction: HCT and Novel Therapy in AML – What are the Implications?


HCT in AML and the Impact of Novel Therapies


Optimizing Post-HCT Outcomes in AML: What Can Clinicians Do?

Robert J. Soiffer, MD

Thoughts on the Changing Role of HCT in AML and Audience Q&A

Jeffrey E. Lancet, MD and Robert J. Soiffer, MD

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

CIBMTR GENERAL ASSEMBLY

2:45 pm – 3:00 pm Florida Hall E

FR

IDA

Y

5555

ASBMT BUSINESS MEETING


BMT TANDEM BEST ABSTRACTS SESSION

3:15 pm – 5:00 pm Florida Hall E Co-Chairs: Marcel R.M. van den Brink, MD, PhD and

David I. Marks, MBBS, PhD

Novel Genetic Variants Associated with Death Due to Acute Lymphoblastic Leukemia within One Year after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT Study)

Theresa E. Hahn, PhD

Ruxolitinib Prevents Cytokine Release Syndrome after CAR T-Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Saad S. Kenderian, MD

A Novel Therapeutic Strategy to Control Conventional T-Cells while Supporting Treg Reconstitution Post-Transplant: Long-Term GVHD-Free Survival By Combining OX40L Blockade with Rapamycin

Victor Tkachev, PhD

Monitoring of MRD before and after Allogeneic Hematopoietic Cell Transplantation of Childhood ALL By FC and RQ-PCR: A Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, the PBMTC, the I-BFM and the Westhafen-Intercontinental-Group

Michael A. Pulsipher, MD

Myeloablative Autologous Transplantation of CD34+ Selected Hematopoietic Stem Cells Versus Monthly Intravenous Cyclophosphamide for Severe Scleroderma with Internal Organ Involvement: Outcomes of a Randomized North American Clinical Trial

Keith Sullivan, MD

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of Inactivated VZV Vaccine in Recipients of Autologous Hematopoietic Cell Transplants

Drew J. Winston, MD

5656

CIBMTR AND ASBMT AWARDS


CIBMTR AWARDS:

CIBMTR Distinguished Service Award Presented to David Gómez-Almaguer, MD and

Guillermo J. Ruiz-Argüelles, MD

The CIBMTR collaborates with the global scientific community to advance HCT and cellular therapy research worldwide. The purpose of the Distinguished Service Award is to recognize individuals who have made outstanding contributions to the CIBMTR’s research mission in one or more of the following areas: promoting HCT research and clinical care in developing countries; advancing the field despite unique challenges; expanding the availability of transplantation; disseminating research results to clinicians and patients to improve outcomes and quality of life; and collaborating with organizations to increase data exchange and research collaboration worldwide.

Dr. David Gómez-Almaguer is head of Hematology at the University Hospital in Monterrey Mexico, and Director of the Stem Cell Transplantation Program, the only FACT accredited program in Mexico. He is a member of the American Society of Hematology, American Society of Clinical Oncology, International Society of Hematology, ASBMT and CIBMTR, and Past President (2009-2011) of Mexican Society of Hematology (AMEH). He was Chair of the CIBMTR’s International Studies Working Committee representing Mexico, Central and South America from 2009-2011. He is a member of the National Academy of Medicine in Mexico, Mexican Academy of Science and National System of Investigators. He is also Secretary General of the Inter-American Division of the International Society of Hematology and President of the Mexican Society of Stem Cell Transplantation. Dr. Gómez-Almaguer has published over 200 articles in Mexican and international journals, and several chapters in books. He is also Editor of the journal Medicina Universitaria, and three books, and has received several awards in recognition for his research.

…continued on next page

5757

Dr. Guillermo J. Ruiz-Argüelles is Director of Research of Clinica Ruiz, founded by his grandfather in 1920, and Director General of the Centro de Hematologia y Medicina Interna de Puebla. He reached the highest level (III) in the Sistema Nacional de Investigadores, and was appointed a member of the Academia Nacional de Medicina, the Academia Mexicana de Ciencias, a fellow of the American College of Physicians (ACP) and of the Royal College of Physicians and Surgeons of Glasgow. He was President of the Mexican Society of Internal Medicine (1989), President of the Mexican Society of Hematology (1994-1995), Chair of Council for the International Society of Hematology (ISH) (2005-2009) and President of ISH (2010-2012). In 2011 he was named Mayo Clinic Distinguished Alumnus, in 2013 he was elected Master of the ACP and in 2016 Governor of the Mexican Chapter of the ACP. Dr. Ruiz-Argüelles has published over 400 papers in peer-reviewed journals, 78 letters to the editor and 356 abstracts. He is the editor of seven books, the editor of the Revista de Hematologìa, and a member of the editorial board of several journals. The main areas of his research and patient care are bone marrow transplantation, treatment of hematological malignancies, coagulation and thrombosis.

Dr. Gómez-Almaguer and Dr. Ruiz-Argüelles receive this award for their service and commitment to the CIBMTR and its missions. They have focused their efforts on making changes to BMT procedures to render them affordable for persons living in developing countries; employing these changes, they have grafted more than 1,000 persons with both malignant and non-malignant diseases.

FR

IDA

Y

5858

ASBMT AWARDS:

ASBMT Lifetime Achievement AwardPresented to Hans Messner, MD, PhD

Dr. Hans Messner is Professor of Medicine at the University of Toronto and Princess Margaret Cancer Centre, Toronto, Ontario, Canada. His legacy to the global transplant com-munity is vast, having contributed substantially to the sci-entific, administrative and educational components of BMT for over four decades. In 1970, he established the first and largest BMT Program in Canada. In doing so, he has trained and mentored scores of Canadian and international BMT trainees, many of whom have since set up their own clinical or research programs in BMT He is the founding President of the Canadian Blood and Marrow Transplant Group (CBMTG), a multidisciplinary organization that represents Canadian health professionals and scientists in the field of BMT. Among his many scientific achievements, was the first description of a clonal assay for human pluripotent hematopoietic progenitors in culture (CFU-GEMM), the first description of pluripotent hematopoietic progenitors in human cord blood, the description of the role of clonogenic progentors in stem cell allografts, and, together with Drs. L. Smith and E.A. McCulloch, the first description of biphenotypic leukemia.

59

FR

IDA

Y

59

BBMT Editorial AwardsErnest McCulloch and James Till Award

Ahmad Rayes, MD

George Santos AwardCarmen Di Grazia, MD

ASBMT New Investigator Awards Each year, the American Society for Blood and Marrow Transplantation is proud to sponsor the research initiatives of new investigators in the field of HCT. We gratefully acknowledge the following sponsors for their generous support of this important initiative:

The ASBMT/Amgen New Investigator Award Supported by ASBMT and Amgen, Inc.

Tessa Minchen Andermann, MD, MPH

The ASBMT/Celgene New Investigator Award Supported by ASBMT and Celgene Corporation

Armin Rashidi, MD, PhD

The ASBMT/Sanofi Genzyme New Investigator Award Supported by ASBMT and Sanofi Genzyme

Ya-Yuan Fu, PhD

The ASBMT/Takeda Oncology New Investigator Award Supported by ASBMT and Millennium, the Takeda Oncology Co.

Shuichiro Takashima, MD, PhD

6060

MORTIMER M. BORTIN LECTURE


Use and Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Era of Targeted Therapies

Richard E. Champlin, MD

Dr. Richard Champlin is currently Professor and Chairman, Department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center in Houston, TX. He has more than 30 years of experience in clinical and translational research involving hematopoietic stem cell transplantation (HCT). Dr. Champlin is also Past President of the American Society of Blood and Marrow Transplantation, and Past Chair of the Advisory Committee for the Center for International Center for Blood and Marrow Transplantation Research. He is a previous Board Member of the National Marrow Donor Program and of the HRSA Advisory Committee for Blood Stem Cell Transplantation. His Department at the MD Anderson Cancer Center has a major research focus to develop novel approaches to improve the efficacy of HCT for treatment of malignancy and hematologic disorders, as well as to prevent the major complications, graft-versus-host disease and infections. He has a major interest in expanding access to HCT for older patients, and patients lacking an HLA-matched donor, using haploidentical and cord blood transplants. Under his direction, MD Anderson Cancer Center has been a leading institution in enrollment of patients on clinical research studies of the BMT CTN and committed to continued enrollment and participation in this important research. His department has a major research focus on cellular therapies and immune modulation to eradicate malignancy and improve disease-free survival. Dr. Champlin is actively investigating the therapeutic use of ex vivo expanded NK cells and chimeric antigen receptor T-Cells to enhance the outcome of HCT and as stand-alone cellular immune therapy.

The Mortimer M. Bortin Lecture commemorates the Founding Scientific Director of the International Bone Marrow Transplant Registry (IBMTR, forerunner of the CIBMTR), whose foresight and dedication were critical to the development of the CIBMTR as a global resource for HCT research. Lecturers are chosen on the basis of their contributions to our understanding of Graft-Versus-Tumor effects and/or the advancement of clinical HCT research.

6161

E. DONNALL THOMAS LECTURE

6:00 pm – 6:30 pmFlorida Hall E

Modulating Immune Reconstitution after Stem Cell Transplantation

Jerome Ritz, MD

Dr. Jerome Ritz is Professor of Medicine, Harvard Medical School. His research laboratory focuses on reconstitution and maintenance of donor immunity after allogeneic hematopoietic stem cell transplantation (HCT). In this setting, there is compelling evidence that donor immunity plays a critical role in elimination of residual tumor cells (termed graft-versus-leukemia or GVL) as well as graft-versus-host disease (GVHD). Individual projects focus on the role of T-Cells, regulatory T-cells, NK cells and B-cells in GVL and GVHD. Mechanistic studies focus on the identification of specific antigenic targets of T, B and NK cell responses and how these immune responses are maintained and regulated in vivo. All of the studies are carried out with samples obtained from patients undergoing stem cell transplantation and lay the foundation for the development of novel methods to specifically modulate immune reconstitution and tumor immunity following HCT. Dr. Ritz is also the Executive Director of the Cell Manipulation Core Facility (CMCF) of the Dana-Farber/Harvard Cancer Center. The CMCF is a GMP cell manufacturing facility that provides a variety of cellular products for patients enrolled on clinical research protocols, including hematopoietic stem cells, cancer vaccines, immune cells for adoptive therapy, genetically modified hematopoietic stem cells and immune cells and cells for regenerative medicine. As well, Dr. Ritz is Director of the Pasquarello Tissue Bank for Hematologic Malignancies at DFCI and Associate Director for Core Facilities and member of the Executive Committee of the Dana-Farber/Harvard Cancer Center.

In honor of Dr. Thomas, the E. Donnall Thomas Lecture recognizes an eminent physician or scientist, either a clinician or investigator, who has contributed meritoriously to the advancement of knowledge in blood and marrow transplantation.

FR

IDA

Y

6262

Saturday, February 25

SATURDAY CONVENTION SERVICES:




SATURDAY EXHIBITS:


2:00 pm – 6:00 pm Exhibit Move-Out Exhibit Hall F

9:00 am – 5:00 pm BMT Tandem Poster Session II Viewing Florida Hall B

6:45 pm – 7:45 pm BMT Tandem Poster Session II – Meet the Authors Florida Hall B Session II Posters must be removed by 9:00 pm on Saturday.

6363

SATURDAY COMMITTEE MEETINGS:Open to All Attendees

12:15 pm – 2:15 pm ASBMT Cord Blood Special Interest Group Meeting Tallahassee 1-3

12:15 pm – 2:15 pm CIBMTR Working Committee Meeting: Infection and Immune Reconstitution Osceola 1-3 Supported by a grant from Astellas Pharma US, Inc.

12:15 pm – 2:15 pm CIBMTR Working Committee Meeting: Pediatric Cancer Osceola 4-6

2:45 pm – 4:45 pm CIBMTR Working Committee Meeting: Chronic Leukemia Osceola 1-3

2:45 pm – 4:45 pm CIBMTR Working Committee Meeting: Donor Health and Safety Naples 1-3

5:00 pm – 5:30 pm ASBMT NP/PA Special Interest Group Business Meeting Osceola C

SA

TU

RD

AY

6464

SATURDAY COMMITTEE MEETINGS:By Invitation

7:00 am – 8:30 am CIBMTR Mismatched Unrelated Donor (15-MMUD) Transplant PI/Coordinators Meetings Sanibel 1-3

7:00 am – 8:30 am NMDP Education Consortium Meeting St. George #112

7:30 am – 8:30 am ASBMT Special Interest Group Chair Meeting with President St. George #104

7:30 am – 8:30 am CIBMTR Kepivance Study Protocol Team Meeting St. George #106

10:00 am – 11:30 am BMT Tandem Scientific Organizing Committee Meeting for 2018 Orange Blossom Ballroom

1:30 pm – 2:30 pm ASBMT Clinical Research Training Course Reunion Emerald Bay Plaza: Wedding Pavilion

4:00 pm – 6:00 pm Transplant Nursing Conference Planning Team Meeting for 2018 Sun 1

5:00 pm – 6:00 pm BMT Pharmacists Conference Planning Meeting for 2018 Osceola A

5:30 pm – 6:30 pm Clinical Education Conference Planning Committee Meeting for 2018 Osceola C

6:30 pm – 7:45 pm Amy Strelzer Manasevit Research Program Reception St. George #114

6565

SATURDAY PERIPHERAL CONFERENCES:

8:15 am – 4:45 pm BMT Pharmacists Conference Osceola A See page 97 for agenda

8:15 am – 6:00 pm BMT Clinical Education Conference (for NPs, PAs, Fellows and Junior Faculty) Osceola C See page 93 for agenda


12:15 pm – 4:45 pm Building a Patient-Centered Outcomes Research (PCOR) Collaborative Community Sun A See page 85 for agenda

BREAKFAST OPTIONS



7:00 am – 8:00 am Optimal Use of Stem Cell Mobilization in Patients with Hematologic Malignancies Florida Hall D

Introduction Parameswaran N. Hari, MD, MS

Barriers to Transplantation in Myeloma Parameswaran N. Hari, MD, MS

Mobilizing Strategies and Goals Luciano J. Costa, MD, PhD

Panel Discussion

This activity is supported by an independent educational grant from Sanofi Genzyme.

SA

TU

RD

AY

6666


7:00 am – 8:00 am Updates on Hematologic Malignancies: New, Targeted Conditioning Regimens Florida Hall E

Welcome and Introduction Sergio A. Giralt, MD

Dose Intensity in MDS and AML: Does it Matter? Bart L. Scott, MD

Novel Conditioning Regimens for Adults with ALL David I. Marks, MBBS, PhD

Clinical Outcomes of New and Emerging Targeted Conditioning Regimens Sergio A. Giralt, MD

Question and Answer Session

This activity is supported by an independent educational grant from Actinium Pharmaceuticals.

6767


ASBMT PRESIDENT’S SYMPOSIUM:

8:30 am – 10:00 am Carpe Diem: Palliative Care, Helping Patients Make the Most of Every Day

The ASBMT President’s Symposium is dedicated to excellence in patient care and provides information, education, professional development and advocacy strategies to promote the delivery of quality blood and marrow transplantation and cellular therapy. The symposium is designed for BMT leaders and covers important current issues. In past years, the focus has been on center factors influencing transplant outcomes, economic outcome measures, reimbursement, overcom-ing current barriers to transplant and systems capacity. The 2017 forum will focus on the growing importance of quality palliative care and its profound impact on HCT patients.

Florida Hall E Chair: Effie Petersdorf, MD

Palliative Care: 21st Century Person-Centered Care for Those Facing a Serious Illness

Thomas W. LeBlanc, MD, MA

Palliative Care Integration in Oncology: The Evidence and Lessons Learned


It’s a Perfect Match: Together HCT and Palliative Care Help Patients Live and Live Well

Christina Ullrich, MD, MPH

10:00 am – 10:30 am – Break

SA

TU

RD

AY

6868


10:30 am – Noon WBMT Joint International Session: Do Stem Cell Transplants Need to Be So Expensive? Florida Hall D Co-Chairs: Yoshihisa Kodera, MD, PhD and

Jeffrey Szer, MBBS

WBMT Introduction Jeffrey Szer, MBBS

Introduction to the Topic of Cost Daniel J. Weisdorf, MD

The Mexican Experience David Gómez-Almaguer, MD

What is Really Necessary? The Indian Experience Alok Srivastava, MD

10:30 am – Noon Chronic GVHD Florida Hall E Chair: Bruce R. Blazar, MD

Preclinical Immune Regulatory Strategies to Treat Chronic GVHD

Bruce R. Blazar, MD

Targeting Tregs in Human Chronic GVHD Jerome Ritz, MD

Chronic GVHD Biomarkers and Application Sophie Paczesny, MD, PhD

10:30 am – Noon Statistical Issues in Transplant Data Florida Hall C Chair: Brent R. Logan, PhD

An Introduction to Adaptive Treatment Strategies Erica C. Moodie, PhD

Flexible Predictive Modeling using Trees and Random Forests

Brent R. Logan, PhD

P-Values in Clinical Research: Friend or Foe? Ted Alan Gooley, PhD

6969

LUNCH OPTIONS

Noon – 1:15 pm – BMT Tandem Buffet Exhibit Hall F



12:15 pm – 1:30 pm How Do I Work-Up and Treat Transplant- Associated Microangiopathy (TAM)? Sun 1

Joseph H. Antin, MD

12:15 pm – 1:30 pm How to Propose a Successful Registry Study with CIBMTR Sun 2



12:30 pm – 1:30 pm Emerging Approaches to Target the Immunologic Chaos of GVHD Florida Hall E

Welcome, Introductions and Baseline Assessment

Corey S. Cutler, MD, MPH

Current Management of Graft-Versus-Host Disease

Corey S. Cutler, MD, MPH, John F. DiPersio, MD, PhD and David Miklos, MD, PhD

Novel and Emerging Therapies for Graft-Versus-Host Disease

Corey S. Cutler, MD, MPH, John F. DiPersio, MD, PhD and David Miklos, MD, PhD

Audience Questions, Post-Activity Assessment

This activity is supported by an educational grant from Incyte Corporation and Pharmacyclics, LLC.

SA

TU

RD

AY

70


4:45 pm – 6:45 pm Oral Abstracts – Session J: Allogeneic Transplants Florida Hall D Moderators: Partow Kebriaei, MD and

Craig S. Sauter, MD

Using Haplogic™ and Recipient Ancestry: The Likelihood of Identifying an 8/8 HLA-Matched Unrelated Donor Can be Accurately Predicted at the Time of the Preliminary Search Markedly Improving Search Efficiency and Speed to Allograft: An 830 Patient Analysis Eric Davis, CHTC

Donor-Lymphocyte Infusion following Haploidentical Hematopoietic Cell Transplantation with Peripheral Blood Stem Cell Grafts and PTCy Scott R. Goldsmith, MD

Maintenance Therapy with Azacitadine and Valproic Acid after Allogeneic Stem Cell Transplant in Patients with High-Risk Acute Myelogenous Leukemia Patrick A. Hagen

Prognostic Impact of Variant Allelic Frequency of Molecular Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes on Allogeneic Hematopoietic Cell Transplant Outcomes Betty Ky Hamilton, MD

Impact of CYP3A5/CYP2C19 Pharmacogenetics on Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation Using Tacrolimus/Sirolimus as Graft-Versus-Host Disease Prophylaxis Samer K. Khaled, MD

High Exposure to Fludarabine in Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation Predicts for Impaired CD4 Reconstitution and Lower Survival Chances Jurgen Langenhorst, PharmD

Allogeneic Transplant for Mixed Phenotype Acute Leukemia: Characteristics and Outcome in the ALWP-EBMT Database Reinhold Munker, MD

71

Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402

Shernan Holtan, MD

4:45 pm – 6:45 pm Oral Abstracts – Session K: Alternative Donors and GVH/GVL Florida Hall E Moderators: Veronika Bachanova, MD, PhD and

Motoko Koyama, MD, PhD

A Novel Pre-Transplant Immunosuppressive Preparative Regimen for Myeloablative Haploidentical and Unrelated Donor Hematopoietic Transplant in Hemoglobinopathies: A Safe and Effective Approach

Sunil Bhat

Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for 41 Children and Adolescents with Bone Marrow Failures

Carmem Bonfim, MD, PhD

Haploidentical Stem Cell Transplantation with CD3+/CD19+ Depleted Peripheral Stem Cells for Advanced Stage Sickle Cell Disease

Selim Corbacioglu, MD

Fevers Post-Infusion of T-Cell Replete HLA-Mismatched Haploidentical Hematopoietic Stem Cells

Melhem Solh, MD

CD56 Enriched Donor Cell Infusion following Post-Transplantation Cyclophosphamide and Cyclosporine Alone for Haploidentical PBSCT in Myeloid Malignancies is Associated with Prompt Reconstitution of Mature NK Cells and Tregs with Reduced Incidence of aGVHD

Sarita Jaiswal, BSc, MD

Analysis of the Impact of Donor Characteristics on Outcomes after 2-Step Haploidentical Hematopoietic Stem Cell Transplantation

Praveen Ramakrishnan Geethakumari, MD

SA

TU

RD

AY

7272

Multi-State Modeling Identifies Determinants of Successful Immune Suppression Discontinuation: Secondary Analysis of BMT CTN 0201 and 0402 Trials Joseph A. Pidala, MD, PhD

Deletion of AMP-Activated Protein Kinase in Donor T-Cells Protects Against Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Responses Craig Alan Byersdorfer, MD, PhD

4:45 pm – 6:45 pm Oral Abstracts – Session L: Allogeneic Transplants and Histocompatibility Florida Hall C Moderators: Leo Luznik, MD and

Lazaros J. Lekakis, MD

Early Clinical Predictors of Hepatic Veno-Occlusive Disease after Myeloablative Hematopoietic Stem Cell Transplantation: A Single-Center Report of 205 Cases Lindsey E. Roeker, MD

Impact of Higher-Dose Total Body Irradiation Conditioning on Outcome of an Allogeneic Hematopoietic Cell Transplant in the Modern Era Mitchell Sabloff, MSc, MDCM

Impact of ABO-Mismatching following HLA- Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation for AML – a Report from the ALWP of the EBMT Bipin N. Savani, MD

Comparable Survival with Organ Toxicity Predicting for Overall Survival and Non-Relapse Mortality in Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation Gunjan L. Shah, MD MS

Allogeneic Hematopoietic Cell Transplantation in the Eighth Decade of Life: How Much Does Age Matter? Mohamed L. Sorror, MD, MSc

7373

Functional Genetic Variants on 14q32 Associate with Death Due to Acute Myeloid Leukemia and Myelodysplastic Syndrome within One Year after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT Study)

Lara Sucheston-Campbell, PhD

Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation

Shannon R. McCurdy, MD

Identifying Permissible HLA-Mismatches in Unrelated-Donor Hematopoietic Stem Cell Transplantation Using Predicted Indirectly Recognizable HLA Epitopes

Eric Spierings, PhD

BMT TANDEM POSTER SESSION II

6:45 pm – 7:45 pm BMT Tandem Poster Session II – Meet the Authors Florida Hall B

Session II Posters must be removed by 9:00 pm on Saturday.

BMT TANDEM MEETINGS RECEPTION:

8:00 pm – 1:00 am Coquina Lawn and Fire Pits/Wreckers Nightclub, Gaylord Palms

Join ASBMT President, Christopher Bredeson, MD, MSc and CIBMTR Chair, Paul J. Martin, MD for an enjoyable evening of conversation, complimentary beverages and cuisine and dancing on Saturday, February 25. The evening will begin on the Coquina Lawn at the Gaylord Palms, then move into Wreckers Nightclub, just off the lawn, for dancing.

Tickets are available online and at the Registration Desk until Thursday, February 23 at 5:00 pm, subject to availability.

SA

TU

RD

AY

7474

Sunday, February 26

SUNDAY CONVENTION SERVICES:




BREAKFAST OPTIONS

6:30 am – 8:15 am – Continental Breakfast Buffet Exhibit Hall Lobby


8:30 am – 10:00 am CAR T-Cells and TCR Gene Therapy Florida Hall E Chair: Emma C. Morris, MD, PhD

Treatment of Lymphoma with Anti-CD19 CAR T-Cells

James N. Kochenderfer, MD

Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: How Close are We?

Saar I. Gill, MD, PhD

TCR Gene Therapy for AML and MDS Emma C. Morris, MD, PhD

10:00 am – 10:30 am – Break

7575


10:30 am – Noon Oral Abstracts – Session M: GVH/GVL Florida Hall D Moderators: James Ferrara, MD, DSc and


Results of a Phase II Clinical Trial of Tocilizumab, Tacrolimus and Methotrexate for the Prevention of Acute Graft-Versus-Host Disease and Matched Case Control Comparison to Tac/MTX after Allogeneic Stem Cell Transplantation William Drobyski, MD

Deficiency of MyD88 Signaling in CD4 Tconvs Increases Tregs Suppression through Loss of ST2 Signaling, Reducing Acute Graft-Versus-Host Disease in Multiple Models Brad Griesenauer, BS

Cytomegalovirus Antigenic Mimicry of Human Alloreactive Peptides: Exploring Cross-Reactivity as a Potential Trigger for Graft-Versus-Host Disease Charles E. Hall, MS

Whole Exome Sequencing to Determine the Likelihood of Graft-Versus-Host Disease in Stem Cell Transplant Donor-Recipient Pairs Amir A. Toor, MD

Biomarkers Predict Graft-Versus-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment Hannah Major-Monfried

Extended Course of Maraviroc, a CCR5 Antagonist, is Safe and Effective in Graft-Versus-Host Disease Prophylaxis. Final Results of a Phase II Study Ran Reshef, MD

10:30 am – Noon Oral Abstracts – Session N: GVH/GVL and Pediatric Disorders Florida Hall E Moderators: Peter Westervelt, MD, PhD and

Kenneth R. Cooke, MD

Production of Antibodies Targeting Surface Membrane Antigens in Patients with Chronic Graft-Versus-Host Disease and Identification of Targeted Antigens Kathy Wang, PhD

SU

ND

AY

7676

Venous Thromboembolism in Pediatric Recipients of Hematopoietic Stem Cell Transplant: A Multicenter Cohort Study

Hemalatha G. Rangarajan, MD

Individualized Dosing and Therapeutic Drug Monitoring of ATG is Feasible, Safe, Effective, and Associated with Excellent Immune Reconstitution

Caroline A. Lindemans, MD, PhD

Interleukin-22 Levels are Increased in Gastrointestinal Graft-Versus-Host Disease in Children

Dana T. Lounder, MD

Vitamin A and Gastrointestinal Graft-Versus-Host Disease in Children: Mechanistic Studies

Dana T. Lounder, MD

Second Hematopoietic SCT for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen

Vikram Mathews, MD

Noon – 12:30 pm – BMT Tandem Buffet Exhibit Hall Lobby

12:30 pm – 1:30 pm Late Breaking Abstracts Florida Hall E Moderators: Marcel R.M. van den Brink, MD, PhD and

David I. Marks, MBBS, PhD

Pivotal Phase 2 Trial of Kte-C19 (anti-CD19 CAR T-Cells) in Patients with Refractory Aggressive NHL (ZUMA-1)

Frederick L. Locke, MD

A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Letermovir for Prevention of Cytomegalovirus Infection in Adult CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation

Francisco M. Marty, MD

Phase 2 Study of Ibrutinib in Patients with Chronic Graft-Versus-Host Disease Who Have Failed Frontline Systemic Therapy

David Miklos, MD, PhD

2017 BMT TANDEM MEETINGS CONCLUDE

7777

CIBMTR Clinical Research Professionals/Data Management Conference

The Clinical Research Professionals/Data Management Conference provides training and educational oppor-tunities to data management staff responsible for com-pleting and submitting recipient data to the CIBMTR.

The Medical College of Wisconsin designates this activity for up to 13.25 hours of participation for continuing education for allied health professionals attending the Clinical Research Professionals/Data Management (CRP/DM) Conference.

Tuesday, February 21

Osceola D

7:00 am – 8:15 am – CRP/DM Breakfast Buffet Osceola D

7:30 am – 8:15 am Breakfast with Dr. Mary M. Horowitz

Mary M. Horowitz, MD, MS

8:15 am – 8:30 am Welcome/Staff Introductions

Sharon K. Meiers and Kay Gardner

8:30 am – 8:45 am Mentors Update

Denise Bellman, CRC and Elizabeth Roberts

8:45 am – 9:30 am CIBMTR Data Life Cycle

J. Douglas Rizzo, MD, MS

9:30 am – 10:00 am VOD

Jennifer R. Willert, MD

10:00 am– 10:30 am – Break

10:30 am – Noon Cellular Therapies – Science, Process, Forms

Bronwen E. Shaw, MD, PhD

Noon – 1:00 pm – CRP/DM Lunch Buffet Osceola D

CLI

NIC

AL

RES

EAR

CH

PR

OFE

SSIO

NA

LS/

DA

TA M

AN

AG

EM

EN

T C

ON

FE

RE

NC

E

78

1:00 pm – 1:45 pm Chronic GVHD


1:45 pm – 2:15 pm CMS Update

Rebecca J. Drexler

2:15 pm – 2:45 pm – Break

2:45 pm – 3:30 pm Molecular Markers

Marcie L. Riches, MD, MS

3:30 pm – 4:15 pm Cytogenetics

Daniel J. Weisdorf, MD

4:15 pm – 4:45 pm Hot Topics

Kay Gardner

5:00 pm – 6:30 pm CRP/DM Mentors’ Reception St. Augustine: Castillo de San Marcos Fort – Upper Level The Mentors’ Reception is a great opportunity to network and meet other Data Managers with whom you can connect throughout the year.


Osceola D

7:30 am – 8:30 am – CRP/DM Breakfast Buffet Osceola D

8:30 am – 8:45 am Welcome

Sharon K. Meiers and Kay Gardner

8:45 am – 9:30 am FACT/CIBMTR Audit Collaboration

Phyllis I. Warkentin, MD

9:30 am – 10:00 am Radiation Injury Treatment Network – Data Collection

Cullen Case

10:00 am – 10:30 am – Break

79

10:30 am – Noon Panel Discussion – Best Practices for Centers Moderator: Bridget Wakaruk, SCM Panelists: Emily Laskowski, Jason Parmentier, BSN, RN

and Daniel Skolnick

Noon – 1:00 pm – CRP/DM Lunch Buffet Osceola D

1:00 pm – 2:00 pm CRP/DM Oral Abstracts

New Quality Improvement Plan for CIBMTR DataNicolette Maria Minas, MS, CCRP and Kathleen Ruehle, RN

Training Tools to Ensure Accurate CIBMTR Data Reporting by New Research Coordinators

Angie Pavlescak

Development of Forms for a Tutorial of Transplant Essential Data as Facilitator to Understand and Learn about Data Entry to CIBMTR in Brazilian Centers

Cinthya Correa Silva

2:00 pm – 2:15 pm – Break

2:15 pm – 3:00 pm Tools for Centers: Data for RFI

Erik Bergman, MBA, MS, Paul Gengler and Read Fritsch

3:00 pm – 3:30 pm Forms Revision Updates/Changes

Emilie Love

3:30 pm – 4:00 pm Method of Latest Disease Assessment

Ashley Birch and Mandi Proue

4:00 pm – 4:45 pm Infection

Marcie L. Riches, MD, MS


St. George #108

1:00 pm – 3:30 pm International Data Managers Open Forum

Janet Brunner-Grady, PA-C, Allyson Draxler, MPH and Bridget Wakaruk, SC

CLI

NIC

AL

RES

EAR

CH

PR

OFE

SSIO

NA

LS/

DA

TA M

AN

AG

EM

EN

T C

ON

FE

RE

NC

E

8080

CRP/DM In-Depth Training

The In-Depth Training for Clinical Research Professionals/Data Management will provide comprehensive training for a limited number of Clinical Research Professionals/Data Managers on subjects including Multiple Myeloma and Forms Journey – The What, When and Where. Registration for the training is available on-site at the BMT Tandem Meetings Registration Desk. Attendance is limited to 15 participants per session, and tickets are subject to availability. Note that only one person from each center may attend each session.

The Medical College of Wisconsin designates this activity for up to 4.0 hours of participation for continuing education for allied health professionals attending the In-Depth Training for Clinical Research Professionals/Data Management.


Sanibel 1-3

9:00 am – 11:30 am SESSION ONE: Basics of Multiple Myeloma

Basics of Multiple Myeloma with Amyloid Anita D’Souza, MD, MS

10:00 am – 10:30 am – Break

Multiple Myeloma Reporting Janet Brunner-Grady, PA-C

1:00 pm – 3:30 pm SESSION TWO: Forms Journey

Andrea Benoit, Leigh Ann Laczkowski, Sue Logan, MS, CCRP, Elliott Michem, Alisha Mussetter and Tina Thole

2:00 pm – 2:30 pm – Break

8181

BMT CTN Investigators Meeting

The BMT CTN Investigators Meeting is for investigators and clinical and research staff involved in BMT CTN studies. Physicians at centers interested in becoming involved in the BMT CTN are also welcome to attend.

The Medical College of Wisconsin designates this live activity for up to 1.0 contact hours of continuing education for allied health professionals attending the BMT CTN Investigators Meeting.


Sun B




7:10 am – 7:30 am BMT CTN 0702 STaMINA Primary Results


7:30 am – 7:45 am BMT CTN 1506 FLT3+ AML Maintenance Therapy

Yi-Bin Chen, MD

7:45 am – 8:00 am BMT CTN 0201 BM Versus PB: Five-Year Follow-Up Results


8:00 am – 8:15 am Risk Stratified Trials in GVHD

Amin M. Alousi, MD

BM

T C

TN

IN

VE

ST

IGA

TO

RS

ME

ET

ING

8282

BMT CTN Coordinators Meeting

The BMT CTN Coordinators Meeting is for BMT CTN clinic and data coordinators, research nurses or other site staff involved with BMT CTN studies.

The Medical College of Wisconsin designates this activity for up to 5.25 hours of participation for continuing education for allied health professionals attending the BMT CTN Coordinators Meeting.


Sun A


8:30 am – 8:35 am Introductions

Ellen Parker, MBA


Adam Mendizabal, PhD

8:55 am – 9:35 am Reporting Toxicities Panel Discussion

Katie McCray, Lisa Murray, MA, Marcie L. Riches, MD, MS and Audra Thompson, RN, BSN

9:35 am – 10:15 am Roundtable Session I

New: BMT CTN Basics and Resources Brianne Allison

Myeloma: Understanding SPEP/UPEP/Free Light Chains/Heavy Light Chains

Kristin Knust, MS and Nina D. Shah, MD

Peds: BMT CTN 1502 Aplastic Anemia Amy E. DeZern, MD, MHS and Iris D. Gersten, MS

Sickle Cell: 1503 HLA-Matched HCT Clinical Protocol Mary Eapen, MD, MS and Courtney Nelson

Ad Hoc: Understanding Statistical Designs Adam Mendizabal, PhD and Maggie Wu, MS

8383

10:15 am – 10:30 am – Break

10:30 am – 11:00 am Single IRB Policy and BMT CTN Implications

Roberta J. King, MPH and Noah Tucker, CCRC

11:00 am – 11:30 am Good Clinical Practices

Denise King, MS

11:30 am – 12:10 pm Roundtable Session II

New: Basic Transplant Science Marcelo C. Pasquini, MD, MS and Terry Pritchard, MS

Myeloma: Common Data Reporting Errors Found by Endpoint Review Committee

Kristin Knust, MS and Philip L. McCarthy, MD

Sickle Cell: BMT CTN 1507 Haplo SCD Brianne Allison and Adetola A. Kassim, MD, MS

Ad Hoc: Core Center Performance Metrics Stacey Brown, Amy Foley, MA, CCRP and Maggie Wu, MS

12:10 pm – 12:45 pm – BMT CTN Lunch Buffet Sun A

12:45 pm – 1:15 pm Preventing and Reporting Deviations

Whitney Reid and Samantha Wilkins

1:15 pm – 1:55 pm Cellular Therapy Clinical Trial Possibilities

Catherine M. Bollard, MD

1:55 pm – 2:35 pm Roundtable Session III

New: Protocol Release to Activation Pathway Terry Pritchard, MS

Myeloma: BMT CTN 1302 and 1401 Lab Samples: Best Practices Ashley Spahn, Stephanie Waldvogel and

Samantha Wilkins

Peds: Toxicities in Children Brianne Allison and Jennifer Baker, RN

Sickle Cell: 1503 Data Management FAQ Courtney Nelson and Mark C. Walters, MD

BM

T C

TN

CO

OR

DIN

AT

OR

S M

EE

TIN

G

8484

Ad Hoc: Methods of Educating Patients about Randomized Clinical Trials Mary Eapen, MD, MS and Iris D. Gersten, MS

2:35 pm – 2:50 pm – Break

2:50 pm – 3:30 pm Sickle Cell Disease: The Care Continuum Mark C. Walters, MD

3:30 pm – 4:15 pm AE Reporting Changes Audra Thompson, RN, BSN

4:15 pm – 4:30 pm Closing Remarks Steven M. Devine, MD

8585

Building a Patient-Centered Outcomes Research (PCOR) Collaborative Community

This session will include interactive discussion presented by patients, caregivers and the co-chairs of six Working Groups: physical health and fatigue; emotional, cognitive and social health; financial burden; models of care delivery-survivorship and late effects; patient, caregiver and family education and support; and sexual health and relationships. Following the Working Group reports, additional research opportunities within PCORI, BMT CTN and CIBMTR will be presented, and we will discuss next steps in building a collaborative research community.

The Medical College of Wisconsin designates this activity for up to 4.0 hours of participation for continuing education for health professionals attending Building a Patient-Centered Outcomes Research (PCOR) Collaborative Community.


Sun A

12:15 pm – 12:30 pm Welcome/Background

Linda J. Burns, MD

12:30 pm – 3:45 pmWorking Groups’ Reports Co-Chair and Patient/Caregiver Co-Presentations

Linda J. Burns, MD

Sexual Health and Relationships Co-Chairs: Allison W. Loren, MD, MScE and

D. Kathryn Tierney, RN, PhD

Physical Health and Fatigue Co-Chairs: William A. Wood, MD, MPH and

Christina Ullrich, MD, MPH

Emotional, Cognitive and Social Health Co-Chairs: Beatrice Abetti, LCSW and


BU

ILD

ING

A P

CO

R C

OL

LA

BO

RA

TIV

E C

OM

MU

NIT

Y

8686

Patient, Caregiver and Family Education and Support Co-Chairs: Kim Schmit-Pokorny, RN, MSN, OCN and

Alva Roche-Green, MD

Models of Survivorship Care Delivery Co-Chairs: Mark B. Juckett, MD and

Lakshmana Krishnamurti, MD

Financial Burden Co-Chairs: Susan Doughtie, MS and

Staci Arnold, MD, MBA

3:45 pm – 4:30 pmResearch Opportunities

Ellen M. Denzen, MS

BMT CTN Mary M. Horowitz, MD, MS

RCI BMT Rebecca J. Drexler

4:30 pm – 4:45 pmNext Steps

Linda J. Burns, MD

8787

Administrative Directors Conference

The Administrative Directors Conference provides updates and education for those involved in BMT program leadership and quality assessment and improvement. Anyone with an interest in quality, staffing, reimbursement and administrative best practices is welcome to attend.

Nursing Education This activity has been submitted to the Oncology Nursing Society (ONS) for approval to award contact hours. ONS is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center’s COA.

Medical Education The Medical College of Wisconsin designates this activity for up to 2.0 hours of participation for continuing education for allied health professionals attending the Administrative Directors Conference Health Economics Session.


Sun A


7:00 am – 7:45 am MEETING CANCELED: Administrative Directors Pre-Conference Demonstration: Administrator Toolkit

8:30 am – 9:00 am Welcome and Special Interest Group Updates

Kent H. Walters, MBA and Tonya P. Cox, BSN, RN, OCN

9:00 am – 10:00 am CIBMTR Updates

J. Douglas Rizzo, MD, MS

10:00 am – 10:15 am – Break

10:15 am – 11:00 am CMS Billing: 2017 Medicare Coding, Billing and Reimbursement Updates: Major Changes to be Aware of!

Jugna Shah, MPH

AD

MIN

IST

RA

TIV

E D

IRE

CT

OR

S C

ON

FE

RE

NC

E

8888

11:00 am – Noon Best Abstracts Presentation

Best Abstracts Opening Presentation Leslie S. Parran, RN, MS, AOCN, NE-BC, BMTCN

Implementation of a Program Assessment Across a Network of 7 HCT Programs to Assess Risks Associated with Clinical Outcome Based on the 2015 Center for International Blood and Marrow Transplant Research Transplant Center-Specific Survival Report

Rocky Billups, MS

Getting Ready for Engineered Cell Therapies – an Administrative Perspective

Amy Emmert, MScPH

Redesigning Care to Lower Episode Costs in Bone Marrow Transplantation

D. Kathryn Tierney, RN, PhD

Noon – 1:15 pm – Lunch Buffet Sun Lobby

1:15 pm – 2:15 pm 2017 Quality: Three Tools for Soaring in High Quality Action

Introduction Therese Dodd, BA, MBA, RN, CPHQ, FNAHQ

When the Worst Happens: Handling Low Occurrences and High-Risk Unforeseen Events

Jennifer A. Christian, CHTC

Defining Competency to Empower Quality Professionals in a Clinical Setting Amanda K. Hrnicek, MBA,LBBA

Setting Quality Standards and Tools for Managing BMT Data

Ryan Hillgruber

2:15 pm – 2:45 pm – Break

2:45 pm – 3:45 pm Quality and Value in SCT Update

Ruth Brentari, MHA3:45 pm – 4:30 pmStaffing and the Transplant Center: BMT Data Management Staffing

Clint L. Divine, MBA, MSM

8989

4:30 pm – 4:45 pm Day One Wrap-up and Flash Evaluations


4:45 pm – 6:00 pm Administrative Directors Conference Reception Sun LobbyThis activity is supported by an independent grant from Sanofi Genzyme.

Friday, February 24Sun A


8:30 am – 9:00 am Welcome and Day Two Review


9:00 am – 10:00 am Staffing Workgroup Presentation: Role of BMT Coordinator

S. Elizabeth Sharf, BSN, RN, NE-BC, CHTC

10:00 am – 10:15 am – Break

10:15 am – 11:15 am Business of HCT Session 1: MACRA and MIPS

Stephanie A. Farnia, MPH

11:15 am – Noon Implementing Cellular Therapies

Partow Kebriaei, MD

Noon – 1:15 pm – Lunch Buffet Sun Lobby

1:15 pm – 2:15 pm Business of HCT Session 2: Economics in HCT and Pharma

Alex Ganetsky, PharmD, BCOP

2:15 pm – 2:30 pm – Break

2:30 – 3:00 pm Day Two Wrap-up, Overall Meeting Evaluations and Call for Volunteers


AD

MIN

IST

RA

TIV

E D

IRE

CT

OR

S C

ON

FE

RE

NC

E

9090

HCT VALUE AND HEALTH ECONOMICS SESSION:

Sun A

3:00 pm – 3:15 pm Introduction to Health Economics and Value Session

Richard T. Maziarz, MD and Linda J. Burns, MD

3:15 pm – 3:55 pm Payer Advocacy Strategies

David Dickens, MD

3:55 pm – 4:15 pm Reimbursement and Drug Pricing: A Physician Perspective

Vinay Prasad, MD, MPH

4:15 pm – 4:35 pm Reimbursement and Drug Pricing: Industry Perspective Nathan J. Dowden

4:35 pm – 4:50 pm Panel Discussion

4:50 pm – 5:10 pm Resource Allocation and Decision Making in Transplant Across National Borders

Lothar B. Huebsch, MD

5:10 pm – 5:30 pm Medical Tourism: Transplant as a Tourist Industry

Kurt C. Gunter, MD

5:30 pm – 5:45 pm Panel Discussion

5:45 pm – 5:55 pm Wrap-Up and Concluding Remarks

Linda J. Burns, MD

9191

BMT Clinical Education Conference (for NPs, PAs, Fellows and Junior Faculty)

This program will update Nurse Practitioners, Physician Assistants, Fellows, and Junior Faculty on key highly applicable research and clinical care topics in the field of blood and marrow transplantation. Through lecture and case-based presentations, specialists in the field will discuss current treatment challenges faced by clinicians involved in the care of both adult and pediatric transplant patients. The Conference will also feature ample opportunity for interactive discussion and question/answer sessions.

The Medical College of Wisconsin designates this activity for up to 11.5 hours of participation for continuing education for allied health professionals attending the BMT Clinical Education Conference.

Friday, February 24

Osceola C


8:15 am – 8:30 amWelcome

Jackie Dioguardi, PA-C

CONCURRENT SESSIONS

8:30 am – 9:15 am

BREAKOUT SESSIONOsceola C BMT 101

Corey S. Cutler, MD, MPH

PEDIATRIC BREAKOUT SESSIONOsceola B Transplant for Neuroblastoma

Gregory A. Yanik, MD

BM

T C

LIN

ICA

L E

DU

CA

TIO

N

CO

NF

ER

EN

CE

9292

9:15 am – 10:00 am

BREAKOUT SESSIONOsceola C Maintenance Therapy after HCT

Bart L. Scott, MD

PEDIATRIC BREAKOUT SESSIONOsceola B Haploidentical Transplant and Gene Therapy for Sickle Cell Disease

Allistair Abraham, MD

10:00 am – 10:30 am – Break

10:30 am – 11:15 am

BREAKOUT SESSIONOsceola C Infectious Diseases in BMT through Images

Francisco M. Marty, MD

PEDIATRIC BREAKOUT SESSIONOsceola B Preventing Graft-Versus-Host Disease in Pediatrics

Sung Won Choi, MD

11:15 am – Noon

BREAKOUT SESSIONOsceola C Neurologic Complications of HCT

Lakshmi Nayak, MD

PEDIATRIC BREAKOUT SESSIONOsceola B Outcomes of Allogeneic Transplant in Pediatric CML

Sonali Chaudhury, MD

Noon – 1:15 pm – Lunch Buffet Osceola Lobby

9393

1:15 pm – 2:00 pm

BREAKOUT SESSIONOsceola C Metabolic Syndrome and Cardiovascular Disease following Hematopoietic Cell Transplantation

Zachariah M. DeFilipp, MD

PEDIATRIC BREAKOUT SESSIONOsceola B Nutrition Management during Pediatric Hematopoietic Cell Transplantation

Paula Charuhas Macris, MS, RD, CSO

2:00 pm – 2:45 pmManaging CAR T-Cell Complications Osceola C

Angela Kirk, PA-C

2:45 pm – 3:30 pmAPPs Interested in Research: Come Get Involved

Randi Hoffmann, PhD, RN, CNP

3:30 pm – 5:30 pm2017 Clinical Education Conference Welcome ReceptionOsceola C


Osceola C


8:15 am – 8:30 amWelcome – Day Two

Jackie Dioguardi, PA-C

8:30 am – 9:15 amAPP Practice Issues: Roundtable Discussions

Surviving and Thriving When Things Don’t Go as Planned

Gabrielle Zecha, PA-C, MHA

9:15 am – 10:00 amSteroid Refractory GVHD

Claudio Anasetti, MD

10:00 am – 10:30 am – Break

BM

T C

LIN

ICA

L E

DU

CA

TIO

N

CO

NF

ER

EN

CE

9494

10:30 am – 11:15 amPreventing and Managing Renal Complications

Benjamin Laskin, MD, MS

11:15 am – NoonBMT Radiology: Pulmonary Manifestations of Bone Marrow Transplant

Aamer Chughtai, MD


1:15 pm – 2:00 pmQuality of Life


2:00 pm – 2:45 pmSequelae of Nuclear Accidents

Robert Peter Gale, MD, PhD

2:45 pm – 3:30 pmMoral Distress

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN

3:30 pm – 4:00 pm – Break

4:00 pm – 5:00 pmNP/PA Oral Abstract Presentations

Rare Case of HHV6 Encephalitis in Post Allogeneic Transplant Recipient

Jamie Reynolds, PA-C

Improving the Percentage of Independent APP Visits: Breaking the “Shared Model” Rut

Chris Rimkus, RN, MSN, AOCN

5:00 pm – 5:30 pmNP/PA Special Interest Group Business Meeting

Open to All Attendees

5:30 pm – 6:00 pmNP/PA Steering Committee Meeting

By Invitation

9595

BMT Pharmacists Conference

The BMT Pharmacists Conference is held annually in conjunction with the BMT Tandem Meetings. During the two-day conference, multiple pharmacy leaders specializing in HCT and experts from other disciplines provide perspective in the clinical management of this complex patient population using an evidence-based approach.

Syntaxx Communications, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Syntaxx Communications has assigned 12.5 contact hours (1.25 CEUs) of continuing pharmacy education credit for this knowledge- and application-based activity. This two-day live conference will incorporate 13 individual activity sessions that combined will fulfill the 12.25 hours of CE. The target audience for this accredited activity is pharmacists. To receive continuing pharmacy education credit for the Conference, participants must attend the sessions in their entirety and complete the associated program evaluation forms.

Additionally, all US-based pharmacists must supply their National Association of Boards of Pharmacy (NABP) elec-tronic Profile Identification (ePID) number and their birth month and day (MM/DD). No credit can or will be issued without this information. To acquire an NABP ePID, go to http://www.nabp.net and click on CPE Monitor. Universal Activity Numbers: 0299-9999-17-001-L01-P through 0299-9999-17-013-L01-P. For questions or issues related to continuing pharmacy education, please contact Syntaxx Communications: [email protected].

Supported by educational grants from Chimerix, Inc. and Pharmacyclics.

Friday, February 24

Osceola A

6:30 am – 8:15 am – Continental Breakfast BuffetExhibit Hall F

8:15 am – 8:30 amWelcome and Overview

Kamakshi V. Rao, PharmD

BM

T P

HA

RM

AC

IST

S C

ON

FE

RE

NC

E

9696

8:30 am – 9:00 amBMT Pharmacists Special Interest Group Update

Alison M. Gulbis, PharmD

9:00 am – 10:15 amAmerican Society of Hematology Update

Karen Sweiss

10:15 am – 10:30 am – Break

10:30 am – 11:30 amThrombotic Microangiopathy in HCT

Sonata Jodele, MD

11:30 am – NoonChallenging Cases – Management of HLH

Karissa Kusick Dominick, PharmD, BCOP


1:15 pm – 2:30 pmNew Drug Update

Laura Kay Whited, PharmD, BCOP

2:30 pm – 2:45 pm – Break

2:45 pm – 4:00 pmBest Pharmacy Abstracts

IV Posaconazole in Pediatric HCTAshley Teusink-Cross, PharmD, MBA, BCPS

Olanzapine for CINV Prevention in Auto HCTTheresa A. Nerone, PharmD

Efficacy of Afternoon Plerixafor Administration Mobilization

Cynthia Elrahi, PharmD

Influence of Body Weight on Melphalan Dosing in Auto HCT

Kendall Shultes, PharmD

4:00 pm – 5:00 pmAntimicrobial Stewardship

Kelly E. Pillinger, PharmD

5:00 pm – 6:00 pmBMT Pharmacists Networking Reception St. Augustine: Castillo de San Marcos Fort – Upper Level

9797


Osceola A


8:15 am – 8:30 amWelcome and Overview

Colleen Timlin, PharmD

8:30 am – 9:30 amPulmonary Complications of Transplant

Alex Ganetsky, PharmD, BCOP

9:30 am – 10:00 amChallenging Cases – HCT in CNS Lymphoma

Anthony J. Proli, PharmD, BCOP, BCPS

10:00 am – 10:15 am – Break

10:15 am – 11:15 amEarly MRD/Relapse in AML

Marcos de Lima, MD

11:15 am – NoonAward Presentations


1:15 pm – 2:15 pmHepatitis C in HCT Patients

Harrys A. Torres, MD

2:15 pm – 2:30 pm – Break

2:30 pm – 3:30 pmGVHD Update

Elizabeth DiMaggio, PharmD, BCOP

3:30 pm – 4:45 pmBest Practices in Stem Cell Mobilization

Kathy Hogan Edwards, PharmD, BCPS, BCOP, Amber Diaz, PharmD, BCOP and Philip Lubanski, PharmD

5:00 pm – 6:00 pm BMT Pharmacist Conference Planning Meeting for 2018

By Invitation

BM

T P

HA

RM

AC

IST

S C

ON

FE

RE

NC

E

9898

Transplant Nursing Conference

The Transplant Nursing Conference will provide current updates and evidence-based practice to improve the quality of care for patients experiencing a BMT. Presentations from multidisciplinary leaders in nursing, medicine and supportive care will address issues that are relevant to nurses and others caring for this patient population, such as symptom management, indications for treatment, patient and family issues, systems related issues and much more. There will be many opportunities for networking and learning what colleagues around the world are doing in practice through oral abstract presentations and the round table sessions.

Registered attendees can earn 17.5 CNE if all educational sessions are attended in their entirety.

The Oncology Nursing Society (ONS) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC’s) Commission on Accreditation. ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Nurses can earn up to an additional 3.0 CNE for viewing the poster abstracts on their own time. For every 19 posters viewed an additional 1.0 CNE can be earned.


6:00 pm – 8:00 pmDrop-In Meet and Greet for First-Time Transplant Nursing Conference Attendees St. George #114

9999


Osceola D


8:30 am – 8:45 amWelcome

Rebecca Martin, BSN, RN, OCN, BMTCN and Mary E. Peterson, MS, APRN, AOCNP

8:45 am – 10:00 amTransfusion-Free Transplant (Bloodless Autologous Stem Cell Transplant)

Cassandra Upchurch, BSN, RN

10:00 am – 10:30 am – Break

10:30 am – NoonDermatologic Issues in Acute GVHD

Amin M. Alousi, MD, Joyce L. Neumann, PhD, APRN, AOCN, BMTCN and Sharon R. Hymes, MD


1:15 pm – 2:15 pmTransplant Nursing Best Abstracts Supported by ONS Foundation

Development of and Compliance with a Vitamin D Monitoring and Supplementation Program for Hematopoietic Stem Cell Transplant Patients

Karen Collum, DNP, RN, OCN

Effect of Increased Activity on Deconditioning in Pediatric Stem Cell Transplant Patients: A Feasibility Study

Heather Marie Taylor, RN, BSN, CPHON

2:15 pm – 2:45 pm – Break

2:45 pm – 4:00 pmEthics and BMT Nursing – Medical Ethics for Transplant Nurses: A Case-Based Discussion

Mary Victoria Weise, RN, BSN, OCN

Supported by ONS Foundation

4:00 pm – 5:15 pmBMT Emergencies

Juan Pinelli, PA-C, MMSc

TR

AN

SP

LA

NT

NU

RS

ING

CO

NF

ER

EN

CE

100100

Friday, February 24

Osceola D


8:30 am – 10:00 amHot Topics – They Transplant for That?

George E. Georges, MD and Bernadette McLaughlin, BSN, RN

10:00 am – 10:30 am – Break

10:30 am – NoonTransplant Nursing Roundtables


1:15 pm – 2:15 pmTransplant Nursing Oral Abstracts

Calcinuerin-Inhibitor Free Graft-Versus-Host Disease Prophylaxis: Its Effects on Magnesium, Renal Function, and the Cost of Care

Marlee Muilenburg, RN, BSN

Coping with Moderate and Severe Chronic Graft-Versus-Host Disease

Jessica P. Driscoll, DNP, ANP-BC

BMTCN® Yes You Can!Amy Patterson, MSN, RN, AOCNS, BMTCN

2:15 pm – 2:45 pm – Break

2:45 pm – 4:00 pmImmunotherapy and the Role of CAR-T – Cellular Immunotherapies – Going Beyond Hematopoietic Cell Transplants

Parameswaran N. Hari, MD, MS

4:00 pm – 5:00 pmTransplant Nursing Special Interest Group Steering Committee MeetingOsceola D

101101


Osceola D


8:30 am – 10:00 amAYA Considerations/Programs

Kyrie Hospodar Magee, CPNP, MSN, RN and Kristen L. Beebe, PA-C

10:00 am – 10:30 am – Break

10:30 am – NoonReproductive Issues in Transplant

Brooke Cherven, RN, MPH, CPON


1:15 pm – 2:15 pmTransplant Nursing Oral Abstracts

Bone Marrow Transplant (BMT) Inpatient Discharge Education: Structured Problem Solving

Chelsea Harding, BSN, RN, OCN

Assessing Needs and Concerns of Autologous and Allogeneic Stem Cell Transplant Survivors at 1-5 Years: A Quality of Life Approach

Lauren E. Brister, NP-C, AOCNP

Not All Positive Cultures are Bad: Improving Work Culture on the PBMT Unit

Kristen Ammon, MSN, RN

2:15 pm – 2:45 pm – Break

2:45 pm – 3:45 pmFresh Outlook Session Learn about the new or unique ways your peers are solving problems in their own practice. Prior to the Poster Session join fellow attendees for moderated discussion to examine how to implement new ideas into your own practice.

4:00 pm – 6:00 pm Transplant Nursing Conference Planning Team Meeting for 2018 Sun 1 By Invitation

TR

AN

SP

LA

NT

NU

RS

ING

CO

NF

ER

EN

CE

102102

2016-2017 ASBMT CommitteesMany special thanks to the volunteer committee members whose work directs the future of the Society:

Committee on Cellular TherapyChairs: Helen E. Heslop, MD

Marcel R.M. van den Brink, MD, PhDMembers: A. John Barrett, MD

Catherine M. Bollard, MD Colleen Delaney, MD, MSc Ardeshir Ghavamzadeh, MD Saar I. Gill, MD, PhD Jonathan A. Gutman, MD Aisha N. Hasan, MD Peiman Hematti, MD Edwin Horwitz, MD Saad S. Kenderian, MD Marcela V. Maus, MD, PhD Robert Negrin, MD Marcelo C. Pasquini, MD, MS Asha B. Pillai, MD Jerome Ritz, MD Elizabeth J. Shpall, MD Jakub Tolar, MD, PhD

Committee on EducationChairs: Mark R. Litzow, MD

Miguel-Angel Perales, MDMembers: Sita D. Bhella, MD

Melissa A. Cochran, RN, NP Luciano J. Costa, MD, PhD Zachariah M. DeFilipp, MD Michael W. Kent, MD Shakila P. Khan, MD Tippu S. Khan, PharmD Andreas K. Klein, MD Amrita Y. Krishnan, MD Adriana K. Malone, MD Muhammad A. Mir, MD Carina G. K. Moravec, ARNP George B. Selby, MD Melisa K. Stricherz, PharmD D. Kathryn Tierney, RN, PhD Auro Viswabandya, MD William A. Wood, MD, MPH

103103

Committee on Education: Subcommittee on Web-Based Learning

Chair: William A. Wood, MD, MPHMembers: Melissa A. Cochran, RN, NP

Luciano J. Costa, MD, PhD Tippu S. Khan, PharmD Andreas K. Klein, MD Mark R. Litzow, MD Miguel-Angel Perales, MD

Committee on Practice GuidelinesChairs: Paul A. Carpenter, MD

Bipin N. Savani, MDMembers: Eric Chow, PharmD

Peter T. Curtin, MD Zachariah M. DeFilipp, MD Suzanne R. Fanning, DO Mehdi Hamadani, MD Betty K. Hamilton, MD Shahrukh K. Hashmi, MD, MPH Yoshi Inamoto, MD Laura J. Johnston, MD Everett Meyer, MD, PhD Mohamad Mohty, MD, PhD Arnon Nagler, MD, MSc Mohamed A. Kharfan-Dabaja, MD Jeanne M. Palmer, MD, MS Miguel-Angel Perales MD Joseph A. Pidala, MD, MS J. Douglas Rizzo, MD, MS Cesar Rodriguez Valdes, MD Jeffrey R. Schriber, MD Nina D. Shah, MD Paul J. Shaughnessy, MD John R. Wingard, MD

20

16

-20

17

AS

BM

T C

OM

MIT

TE

ES

104104

Committee on Quality OutcomesChairs: Roy B. Jones, MD, PhD

Navneet S. Majhail, MD, MS Members: Peggy L. Appel, MHA

Javier Bolanos-Meade, MD Sara Close, PA-C Sarah A. Cooley, MD, ex-officio Helen E. Heslop, MD Madan H. Jagasia, MD Mark B. Juckett, MD C. Fred LeMaistre, MD Leslie S. Parran, RN Michael A. Pulsipher, MD J. Douglas Rizzo, MD, MS Janet Sirilla, RN, MSN Mohamed L. Sorror MD, MSc Kimberly E. Thormann, APN

Committee on Quality Outcomes: Subcommittee on InformaticsChairs: Roy B. Jones, MD, PhD

Charles Martinez, BS Sarah A. Cooley, MD

Members: Matthew J. Kastigar, MBA Thomas R. Klumpp, MD Marcia Latiff Martin Maiers, BA David Patton, PA-C, MPAS Jane Pollack Dianne M. Reeves, CFRE Ramona T. Repaczki-Jones, MSE J. Douglas Rizzo, MD, MS Keith Stockerl-Goldstein, MD Richard Vinesett

Committee on RFIChair: Patrick J. Stiff, MDVice Chair: Kent H. Walters, MBAMembers: Stephanie A. Farnia, MPH

Thomas R. Klumpp, MD C. Fred LeMaistre, MD Navneet S. Majhail, MD, MS Michael I. Rabin, MBA, MPA J. Douglas Rizzo, MD, MS William P. Vaughan, MD

105105

ASBMT Special Interest GroupsSteering Committee of the BMT CenterAdministrative Directors Special Interest GroupChair: Tonya P. Cox, BSN, RN, OCN Members: Clint L. Divine, MBA, MSM

Myrlena Lee, MBA Leslie S. Parran, RN, MS, AOCN, NE-BC Kent H. Walters, MBA Vandana Rangnekar (Affiliate Member)

Steering Committee of the Cord Blood Special Interest GroupChairs: Juliet N. Barker, MBBS

Elizabeth J. Shpall, MD Members: Joanne Kurtzberg, MD

Claudio Brunstein, MD, PhD Colleen Delaney, MD, MSc

Steering Committee of the HCT Survivorship Special Interest GroupChairs: Shahrukh K. Hashmi, MD, MPH

Linda J. Burns, MD Members: New Committee – Members TBD

Steering Committee of the HCT Value and Health Economics Special Interest GroupChairs: Richard T. Maziarz, MD

Linda J. Burns, MD Members: Rocky Billups, MS

Gregory A. Yanik, MD Guillermo J. Ruiz-Argüelles, MD Theresa E. Hahn, PhD Dave Vanness, Consultant

Steering Committee of the NP/PA Special Interest GroupChair: Jackie V. Dioguardi, MSHS, PA-C

Heather M. Hylton, PA-C, Chair-Elect Susan M. Ferrey, PA-C, Outgoing Chair

Members: Brenda L. Frye, PA-C, DHSc Randi Hoffman, PhD, RN Amy Joyce, MSN, NP, AOCN Carina G.K. Moravec, ARNP Pamela Paplham, DNP, AOCNP, FNP-BC Nancy Shreve, APN, FNP-BC Julie E. Wilhauk, DNP, AOCNP, FNP-BC

20

16

-20

17

AS

BM

T C

OM

MIT

TE

ES

106

Steering Committee of the Palliative Care Special Interest GroupChairs: Effie Petersdorf, MD

Thomas W. LeBlanc, MD, MA Members: New Committee – Members TBD

Steering Committee of the Pediatric Special Interest GroupChair: Michael A. Pulsipher, MD Members: Carl Allen, MD

Jeffrey J. Auletta, MD K. Scott Baker, MD, MS Terry J. Frey, MD Steven A. Grupp, MD, PhD Alex Y. Huang, MD, PhD Carrie L. Kitko, MD John E. Levine, MD, MS Franco Locatelli, MD Rebecca A. Marsh, MD Margaret L. MacMillan, MD, MSc Julie M. Talano, MD Michael R. Verneris, MD Paul Veys, MBBS Gregory A. Yanik, MD

Steering Committee of the Pharmacy Special Interest GroupChair: Alison M. Gulbis, PharmD Members: Tippu S. Khan, PharmD

Joseph S. Bubalo, PharmD Jeffrey A. Butcher, PharmD Amber B. Clemmons, PharmD, BCOP Alex Ganetsky, PharmD LeAnne D. Kennedy, PharmD

Steering Committee of the Transplant Infectious Diseases Special Interest GroupChairs: Roy F. Chemaly, MD, MPH

Michael J. Boeckh, MD, PhD Members: Aliyah Baluch, MD, MSc

Kieren A. Marr, MD Janet A. Englund, MD Ella J. Ariza-Heredia, MD Sherif B. Mossad, MD

107

Steering Committee of the Transplant Nursing Special Interest GroupChair: Chris Rimkus, RN, MSNMembers: Margaret Bellerjeau, RN, MSN, OCN, CHTC

Suni D. Elgar, RN Jennifer B. Frith, RN, BSN, OCN Rebecca Gonzales, RN, BS, MA Stephanie Jardine, RN, MSN Elizabeth Murphy, EdD, RN, ex-officio Joyce L. Neumann, PhD, APRN, AOCN, BMTCN Lisa Pinner, RN, MSN, CPON, BMTCN D. Kathryn Tierney, RN, PhD, ex-officio

20

16

-20

17

AS

BM

T C

OM

MIT

TE

ES

108108

CIBMTR Working Committee Meetings Schedule-at-a-GlanceThe Medical College of Wisconsin designates this live activity for a maximum of 14.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


12:15 pm – 2:15 pm Plasma Cell Disorders and Adult Solid TumorsNaples 1-3

12:15 pm – 4:45 pm ImmunobiologyOsceola 1-3

2:45 pm – 4:45 pm Late Effects and Quality of LifeNaples 1-3

2:45 pm – 4:45 pm Primary Immune Deficiencies, Inborn Errors of Metabolism and Other Non-Malignant Marrow DisordersOsceola 4-6


12:15 pm – 2:15 pm Acute LeukemiaOsceola 4-6

12:15 pm – 2:15 pm Autoimmune Diseases and Cellular TherapiesOsceola 1-3

2:45 pm – 4:45 pm Graft Sources and ManipulationOsceola 4-6

2:45 pm – 4:45 pm LymphomaOsceola 1-3

109109

Friday, February 24

12:15 pm – 2:15 pm Graft-Versus-Host DiseaseOsceola 4-6 Supported by a grant from Gilead Sciences, Inc.

12:15 pm – 2:15 pm Health Services and International StudiesOsceola 1-3

12:15 pm – 2:15 pm Regimen-Related ToxicityNaples 1-3


12:15 pm – 2:15 pm Infection and Immune ReconstitutionOsceola 1-3 Supported by a grant from Astella Pharma US, Inc.

12:15 pm – 2:15 pm Pediatric CancerOsceola 4-6

2:45 pm – 4:45 pm Chronic LeukemiaOsceola 1-3

2:45 pm – 4:45 pm Donor Health and SafetyNaples 1-3 C

IBM

TR

WO

RK

ING

CO

MM

ITT

EE

ME

ET

ING

S S

CH

ED

UL

E-A

T-A

-GL

AN

CE

110110

CIBMTR Working Committee Leadership and StaffAcute Leukemia Chairs: Marcos J.G. de Lima, MD

Brenda M. Sandmaier, MD Hanna J. Khoury, MD

Scientific Director: Daniel J. Weisdorf, MD Assistant Scientific Director: Wael Saber, MD, MS Statistical Director: Mei-Jie Zhang, PhD Statistician: Hailin Wang, MPH

Autoimmune Diseases and Cellular TherapiesChairs: Ian Lewis, MBBS, PhD

David McKenna, MD Stefanie Sarantopoulos, MD, PhD

Scientific Director: Marcelo C. Pasquini, MD, MS Statistical Director: Ruta Brazauskas, PhD Statistician: Kyle Bo-Subait, MPH

Chronic LeukemiaChairs: Edwin Alyea, MD

Uday R. Popat, MD Ronald Sobecks, MD

Scientific Director: Wael Saber, MD, MS Statistical Directors: Kwang Woo Ahn, PhD

Ying Liu, PhD Statistician: Zhenhuan Hu, MPH

Donor Health and SafetyChairs: Galen E. Switzer, PhD

Michael A. Pulsipher, MD Nirali Shah, MD, MHSc

Scientific Director: Bronwen E. Shaw, MD, PhD Associate Scientific Director: Dennis L. Confer, MD Statistical Director: Brent R. Logan, PhD Statisticians: Deidre Kiefer, MPH

Pintip Chitphakdithai, PhDCAC Representatives: Maureen Beamen

Beatrice Abetti, MSW, LCSW Jeffrey Haertling

Graft Sources and ManipulationChairs: Miguel-Angel Perales, MD

Vanderson Rocha, MD, PhD Asad Bashey, MD, PhD

Scientific Director: Mary Eapen, MD, MS Statistical Director: Mei-Jie Zhang, PhD Statistician: Andrew St. Martin, MS

111111

Graft-Versus-Host DiseaseChairs: Daniel R. Couriel, MD, MS

Amin M. Alousi, MD Joseph A. Pidala, MD, PhD

Scientific Directors: Mukta Arora, MD, MS Stephen R. Spellman, MBS

Statistical Directors: Tao Wang, PhD Ying Liu, PhD

Statistician: Michael Hemmer, MSCAC Representatives: Hilary N. Hall

Jim Omel, MD

Health Services and International StudiesChairs: Carmem M. Sales-Bonfim, MD

Jignesh Dalal, MD Theresa E. Hahn, PhD Nandita Khera, MD

Scientific Director: Wael Saber, MD, MSStatistical Director: Ruta Brazauskas, PhD Statistician: Naya He, MPHCAC Representatives: Gerardo Camarillo, JD

Jack Aiello

ImmunobiologyChairs: Michael R. Verneris, MD

Katharina Fleischhauer, MD Katharine Hsu, MD, PhD

Scientific Directors: Stephanie J. Lee, MD, MPH Stephen R. Spellman, MBS

Statistical Director: Tao Wang, PhD Statistician: Michael Haagenson, MS

Infection and Immune ReconstitutionChairs: Jeffery Auletta, MD

Caroline A. Lindemans, MD, PhD Krishna V. Komanduri, MD

Scientific Director: Marcie L. Riches, MD, MSStatistical Director: Soyoung Kim, PhDStatistician: Min Chen, MS

Late Effects and Quality of LifeChairs: Bipin N. Savani, MD

Mary E.D. Flowers, MD Minoo Battiwalla, MD, MS

Scientific Director: Bronwen E. Shaw, MD, PhDStatistical Director: Ruta Brazauskas, PhD Statistician: Heather Millard, MPHCAC Representatives: Kristen Scheeler

Barry Schatz CIB

MT

R W

OR

KIN

G C

OM

MIT

TE

EL

EA

DE

RS

HIP

AN

D S

TAF

F

112

LymphomaChairs: Sonali Smith, MD

Anna Sureda, MD Timothy S. Fenske, MD, MS

Scientific Director: Mehdi Hamadani, MDStatistical Director: Kwang Woo Ahn, PhD Statistician: Alyssa DiGilio, MS

Pediatric CancerChairs: Gregory Hale, MD

Parinda Mehta, MD Angela Smith, MD, MS

Scientific Director: Mary Eapen, MD, MSStatistical Director: Kwang Woo Ahn, PhD Statistician: Heather Millard, MPH

Plasma Cell Disorders and Adult Solid TumorsChairs: Amrita Y. Krishnan, MD, FACP

Cristina Gasparetto, MD Yago Neito, MD, PhD Tomer Mark, MD

Scientific Director: Parameswaran N. Hari, MD, MS Assistant Scientific Director: Anita D’Souza, MD, MS Statistical Director: Raphael Fraser, PhDStatistician: Omar Davila, MPHCAC Representative: Jim Omel, MD

Primary Immune Deficiencies, Inborn Errors of Metabolism and Other Non-Malignant Marrow DisordersChairs: Paolo Anderlini, MD

Neena Kapoor, MD Jaap-Jan Boelens, MD, PhD Vikram Mathews, MD

Scientific Director: Mary Eapen, MD, MSStatistical Director: Soyoung Kim, PhD Statistician: Kyle Hebert, MS

Regimen-Related Toxicity and Supportive CareChairs: Andrew S. Artz, MD, MS

Alison W. Loren, MD, MS Shin Mineishi, MD

Scientific Director: Marcelo C. Pasquini, MD, MSStatistical Director: Brent R. Logan, PhD Statistician: Xiaochun Zhu, MS

113

Invited Faculty BMT Tandem Scientific MeetingTobias Alexander, MD Charite-Universitätsmedizin Berlin Berlin, Germany

Kenneth C. Anderson, MD Dana-Farber Cancer Institute Boston, MA

Joseph H. Antin, MD Dana-Farber Cancer Institute, Harvard Medical School Boston, MA

Andrew S. Artz, MD, MS University of Chicago School of Medicine Chicago, IL

David E. Avigan, MD Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA

Veronika Bachanova, MD, PhD University of Minnesota Minneapolis, MN

Juliet N. Barker, MBBS Memorial Sloan Kettering Cancer Center New York, NY

Minoo Battiwalla, MD, MS National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, MD

Bruce R. Blazar, MD University of Minnesota Minneapolis, MN

Michael J. Boeckh, MD Fred Hutchinson Cancer Research Center Seattle, WA

Michael Boo, JD National Marrow Donor Program/Be The Match Minneapolis, MN

Linda J. Burns, MD National Marrow Donor Program/Be The Match Minneapolis, MN

INV

ITE

D F

AC

ULT

Y

114114

Jose F. Camargo, MD University of Miami, Miller School of Medicine Miami, FL

Richard E. Champlin, MD UT MD Anderson Cancer Center Houston, TX

Robert Chen, MD City of Hope National Medical Center Duarte, CA

Kenneth R. Cooke, MD Johns Hopkins Kimmel Cancer Center Baltimore, MD

Corey S. Cutler, MD, MPH Dana-Farber Cancer Institute Boston, MA

H. Joachim Deeg, MD Fred Hutchinson Cancer Research Center Seattle, WA

Steven M. Devine, MD The Ohio State University Comprehensive Cancer Center Columbus, OH

John F. DiPersio, MD, PhD Washington University School of Medicine St. Louis, MO

Peter Dreger, MD, PhD University Hospital Heidelberg, Germany

Hermann Einsele, MD Universitätsklinikum Würzburg Würzburg, Germany

Areej R. El-Jawahri, MD Massachusetts General Hospital Boston, MA

Stephanie A. Farnia, MPH ASBMT Arlington Heights, IL

Timothy S. Fenske, MD, MS Medical College of Wisconsin Milwaukee, WI

James Ferrara, MD, DSc Icahn School of Medicine at Mount Sinai New York, NY

Luciano J. Costa, MD, PhDUniversity of AlabamaBirmingham, AL

115115

Saar I. Gill, MD, PhD University of Pennsylvania Philadelphia, PA

Sergio A. Giralt, MD Memorial Sloan Kettering Cancer Center New York, NY

David Gómez-Almaguer, MD Universidad Autonoma de Nuevo Leon Monterrey, Mexico

Ted Alan Gooley, PhD Fred Hutchinson Cancer Research Center Seattle, WA

Stephan A. Grupp, MD, PhD The Children’s Hospital of Philadelphia Philadelphia, PA

Vikas Gupta, MD Princess Margaret Cancer Center Toronto, Canada

Mehdi Hamadani, MD Medical College of Wisconsin Milwaukee, WI

Alan M. Hanash, MD, PhD Memorial Sloan Kettering Cancer Center New York, NY

Parameswaran N. Hari, MD, MS Medical College of Wisconsin Milwaukee, WI

Helen E. Heslop, MD Baylor College of Medicine Houston, TX

Ernst Holler, MD, PhD University of Regensburg Regensburg, Germany

Richard J. Jones, MD Johns Hopkins University School of Medicine Baltimore, MD

Christopher G. Kanakry, MD National Cancer Institute, National Institutes of Health Bethesda, MD

Partow Kebriaei, MD UT MD Anderson Cancer Center Houston, TX

INV

ITE

D F

AC

ULT

Y

116116

Natasha Kekre, MD, MPH The Ottawa Hospital Ottawa, Canada

Carrie L. Kitko, MD Vanderbilt University Medical Center Nashville, TN

James N. Kochenderfer, MD National Cancer Institute, National Institutes of Health Bethesda, MD

Yoshihisa Kodera, MD, PhD Aichi Medical University, School of Medicine Nagakute/Aichi, Japan

Dimitrios P. Kontoyiannis, MD UT MD Anderson Cancer Center Houston, TX

John Koreth, MBBS, DPhil Dana-Farber Cancer Institute Boston, MA

Motoko Koyama, MD, PhD QIMR Berghofer Medical Research Institute Brisbane, Australia

Nicolaus Kröger, MD University Hospital Eppendorf Hamburg, Germany

Shaji Kumar, MD Mayo Clinic Rochester, MN

Jeffrey E. Lancet, MD H. Lee Moffitt Cancer Center & Research Institute Tampa, FL

Hillard M. Lazarus, MD University Hospitals Cleveland Medical Center Cleveland, OH

Thomas W. LeBlanc, MD, MA Duke Cancer Institute Durham, NC

Ann M. Leen, PhD Baylor College of Medicine Houston, TX

Lazaros J. Lekakis, MD University of Miami Miami, FL

117117

Brent R. Logan, PhD Medical College of Wisconsin Milwaukee, WI

Leo Luznik, MD Johns Hopkins University School of Medicine Baltimore, MD

Margaret L. MacMillan, MD, MSc University of Minnesota Minneapolis, MN

Navneet S. Majhail, MD, MS Cleveland Clinic Taussig Cancer Institute Cleveland, OH

David I. Marks, MBBS, PhD University Hospitals Bristol NHS Trust Bristol, United Kingdom

Rebecca A. Marsh, MD Cincinnati Children’s Hospital Medical Center Cincinnati, OH

Everett Meyer, MD, PhD Stanford University Stanford, CA

David Miklos, MD, PhD Stanford University Stanford, CA

Erica C. Moodie, PhD McGill University Montreal, Canada

Emma C. Morris, MD, PhD University College London London, United Kingdom

Robert Negrin, MD Stanford University Stanford, CA

Nicolas Novitzky, MD, PhD University of Cape Town Medical School Cape Town, South Africa

Richard J. O’Reilly, MD Memorial Sloan Kettering Cancer Center New York, NY

Sophie Paczesny, MD, PhD Indiana University Indianapolis, IN

INV

ITE

D F

AC

ULT

Y

118118

Marcelo C. Pasquini, MD, MS CIBMTR and Medical College of Wisconsin Milwaukee, WI

Effie Petersdorf, MD Fred Hutchinson Cancer Research Center Seattle, WA

Jerome Ritz, MD Dana-Farber Cancer Institute, Harvard Medical School Boston, MA

Rizwan Romee, MD Washington University School of Medicine St. Louis, MO

Ashley Rosko, MD Ohio State University Columbus, OH

Montserrat Rovira, MD, PhD Hospital Clinic Barcelona, Spain

Guillermo J. Ruiz-Argüelles, MD Clinica Ruiz Puebla, Mexico

Brenda M. Sandmaier, MD Fred Hutchinson Cancer Research Center Seattle, WA

Craig S. Sauter, MD Memorial Sloan Kettering Cancer Center New York, NY

Bart L. Scott, MD Fred Hutchinson Cancer Research Center Seattle, WA

Bronwen E. Shaw, MD, PhD CIBMTR and Medical College of Wisconsin Milwaukee, WI

Thomas C. Shea, MD University of North Carolina Chapel Hill, NC

John A. Snowden, MD Sheffield Teaching Hospitals Sheffield, United Kingdom

Robert J. Soiffer, MD Dana-Farber Cancer Institute, Harvard Medical School Boston, MA

119119

Matthew Spitzer, PhD University of California, San Francisco San Francisco, CA

Alok Srivastava, MD Christian Medical College Vellore, India

Rainer Storb, MD Fred Hutchinson Cancer Research Center Seattle, WA

Jeffrey Szer, MBBS Royal Melbourne Hospital Parkville, Australia

André Tichelli, MD University Hospital Basel Basel, Switzerland

Laurel Todd, MBA Biotechnology Innovation Organization Washington, DC

Christina Ullrich, MD, MPH Boston Children’s Hospital/Dana-Farber Cancer Institute Boston, MA

Luca Vago, MD, PhD San Raffaele Scientific Institute Milano, Italy

Marcel R.M. van den Brink, MD, PhD Memorial Sloan Kettering Cancer Center New York, NY

Jeremy Walston, MD Johns Hopkins University School of Medicine Baltimore, MD

Kent H. Walters, MBA UT MD Anderson Cancer Center Houston, TX

Daniel J. Weisdorf, MD University of Minnesota Minneapolis, MN

Peter Westervelt, MD, PhD Washington University School of Medicine St. Louis, MO

John R. Wingard, MD University of Florida Gainesville, FL

INV

ITE

D F

AC

ULT

Y

120120

Catherine Wu, MD Dana-Farber Cancer Institute Boston, MA

Anas Younes, MD Memorial Sloan Kettering Cancer Center New York, NY

Invited Faculty Pediatric BMT ProgramCarl Allen, MD Baylor College of Medicine, Texas Children’s Hospital Houston, TX

Christopher Bredeson, MD, MSc The Ottawa Hospital, University of Ottawa Ottawa, Canada

Andrew C. Dietz, MD, MSCR Children’s Hospital Los Angeles Los Angeles, CA


Terry Fry, MD National Cancer Institute, National Institutes of Health Bethesda, MD

Cynthia A. Gerhardt, PhD The Research Institute at Nationwide Children’s Hospital Columbus, OH

Elie Haddad, MD, PhD Ste-Justine Hospital Montreal, Canada

Alex Huang, MD, PhD Case Western Reserve University Cleveland, OH

Sonata Jodele, MD Cincinnati Children’s Hospital Medical Center Cincinnati, OH

Carrie L. Kitko, MD Vanderbilt University Medical Center Nashville, TN

121121

John Letterio, MD University Hospital Cleveland Medical Center and Case Western Reserve University Cleveland, OH

Margaret L. MacMillan, MD, MSc University of Minnesota Minneapolis, MN

Ivan Maillard, MD, PhD University of Michigan Ann Arbor, MI

Rebecca A. Marsh, MD Cincinnati Children’s Hospital Medical Center Cincinnati, OH

Booki Min, PhD Cleveland Clinic Cleveland, OH

Michael A. Pulsipher, MD Children’s Hospital Los Angeles Los Angeles, CA

Galen E. Switzer, PhD University of Pittsburgh Pittsburgh, PA

David T. Teachey, MD Children’s Hospital of Philadelphia Philadelphia, PA

Danielle Townsley, MD, MSc National Heart, Lung and Blood Institute National Institutes of Health Bethesda, MD

Lucie Turcotte, MD Masonic Cancer Center Minneapolis, MN

Paul Veys, MBBS Great Ormond Street Hospital for Children London, United Kingdom

John E. Wagner, MD University of Minnesota Minneapolis, MN

INV

ITE

D F

AC

ULT

Y

122122

Invited Faculty Clinical Research Professionals/ Data Management ConferenceDenise Bellman, CRC Cincinnati Children’s Hospital Medical Center Cincinnati, OH

Ashley Birch CIBMTR, NMDP/Be The Match Minneapolis, MN

Cullen Case CIBMTR, NMDP/Be The Match Minneapolis, MN

Rebecca J. Drexler CIBMTR, NMDP/Be The Match Minneapolis, MN

Read Fritsch CIBMTR, NMDP/Be The Match Minneapolis, MN

Kay Gardner CIBMTR, NMDP/Be The Match Minneapolis, MN

Paul Gengler CIBMTR/Medical College of Wisconsin Milwaukee, WI

Mary M. Horowitz, MD, MS CIBMTR and Medical College of Wisconsin Milwaukee, WI

Emily Laskowski University of Kansas Kansas City, KS

Stephanie J. Lee, MD, MPH Fred Hutchinson Cancer Research Center Seattle, WA

Emilie Love CIBMTR, NMDP/Be The Match Minneapolis, MN

Sharon K. Meiers CIBMTR/Medical College of Wisconsin Milwaukee, WI

Erik Bergman, MBA, MSCIBMTR/Medical College of WisconsinMilwaukee, WI

123123

Jason Parmentier, BSN, RN Barnes Jewish Hospital St. Louis, MO

Mandi Proue CIBMTR, NMDP/Be The Match Minneapolis, MN

Marcie L. Riches, MD, MS University of North Carolina Chapel Hill, NC

J. Douglas Rizzo, MD, MS CIBMTR and Medical College of Wisconsin Milwaukee, WI

Elizabeth Roberts Cincinnati Children’s Hospital Medical Center Cincinnati, OH

Bronwen E. Shaw, MD, PhD CIBMTR and Medical College of Wisconsin Milwaukee, WI

Daniel Skolnick Massachusetts General Hospital Boston, MA

Bridget Wakaruk, SCM CIBMTR, NMDP/Be The Match Minneapolis, MN

Phyllis I. Warkentin, MD University of Nebraska Medical Center Omaha, NE

Daniel J. Weisdorf, MD University of Minnesota Minneapolis, MN

Jennifer R. Willert, MD Children’s Hospital San Diego San Diego, CA

Invited Faculty CRP/DM In-Depth TrainingAndrea Benoit CIBMTR/Medical College of Wisconsin Milwaukee, WI

INV

ITE

D F

AC

ULT

Y

124124

Janet Brunner-Grady, PA-C CIBMTR/Medical College of Wisconsin Milwaukee, WI

Anita D’Souza, MD, MS Medical College of Wisconsin Milwaukee, WI

Leigh Ann Laczkowski CIBMTR/Medical College of Wisconsin Milwaukee, WI

Sue Logan, MS, CCRP CIBMTR, NMDP/Be The Match Minneapolis, MN

Elliott Michem CIBMTR/Medical College of Wisconsin Milwaukee, WI

Alisha Mussetter CIBMTR, NMDP/Be The Match Minneapolis, MN

Tina Thole CIBMTR, NMDP/Be The Match Minneapolis, MN

Invited Faculty BMT CTN Investigators MeetingAmin M. Alousi, MD UT MD Anderson Cancer Center Houston, TX

Yi-Bin Chen, MD Massachusetts General Hospital Boston, MA


Stephanie J. Lee, MD, MPH Fred Hutchinson Cancer Research Center Seattle, WA


125125

Invited Faculty BMT CTN Coordinators MeetingBrianne Allison The Emmes Corporation Rockville, MD

Jennifer Baker, RN Duke University Medical Center Durham, NC

Catherine M. Bollard, MD Children’s National Medical Center Washington, DC

Stacey Brown Northside Hospital Cancer Institute Atlanta, GA


Amy E. DeZern, MD, MHS Johns Hopkins University School of Medicine Baltimore, MD

Mary Eapen, MD, MS CIBMTR and Medical College of Wisconsin Milwaukee, WI

Amy Foley, MA, CCRP National Marrow Donor Program Minneapolis, MN

Iris D. Gersten, MS The Emmes Corporation Rockville, MD

Adetola Kassim, MD, MS Vanderbilt University Medical Center Nashville, TN

Denise King, MS The Emmes Corporation Rockville, MD

Roberta J. King, MPH CIBMTR, NMDP/Be The Match Minneapolis, MN

Kristin Knust, MS The Emmes Corporation Rockville, MD

INV

ITE

D F

AC

ULT

Y

126126

Philip L. McCarthy, MD Roswell Park Cancer Institute Buffalo, NY

Katie McCray Ohio State University Medical Center Columbus, OH

Adam Mendizabal, PhD The Emmes Corporation Rockville, MD

Lisa Murray, MA Washington University St. Louis, MO

Courtney Nelson The Emmes Corporation Rockville, MD

Ellen Parker, MBA The Emmes Corporation Rockville, MD


Terry Pritchard, MS The Emmes Corporation Rockville, MD

Whitney Reid Weill Cornell University New York, NY

Marcie L. Riches, MD, MS University of North Carolina Chapel Hill, NC

Nina D. Shah, MD University of California San Francisco, CA

Ashley Spahn CIBMTR/National Marrow Donor Program Minneapolis, MN

Audra Thompson, RN, BSN The Emmes Corporation Rockville, MD

Noah Tucker, CCRC Johns Hopkins University School of Medicine Baltimore, MD

127127

Stephanie Waldvogel CIBMTR/National Marrow Donor Program Minneapolis, MN

Mark C. Walters, MD Children’s Hospital of Oakland Oakland, CA

Samantha Wilkins The Emmes Corporation Rockville, MD

Maggie Wu, MS The Emmes Corporation Rockville, MD

Invited Faculty Administrative Directors ConferenceRuth Brentari, MHA Kaiser Permanente Oakland, CA

Jennifer A. Christian, CHTC University of Kentucky Medical Center Lexington, KY

Tonya P. Cox, BSN, RN, OCN Sarah Cannon Denver, CO

Clint L. Divine, MBA, MSM University of Kansas Cancer Center Westwood, KS

Therese Dodd, BA, MBA, RN, CPHQ, FNAHQ Sarah Cannon Nashville, TN


Alex Ganetsky, PharmD, BCOP University of Pennsylvania Philadelphia, PA

Ryan Hillgruber H. Lee Moffitt Cancer Center Tampa, FL

Amanda K. Hrnicek, MBA, LBBA Ohio State University, James Cancer Hospital Columbus, OH

INV

ITE

D F

AC

ULT

Y

128128

Partow Kebriaei, MD UT MD Anderson Cancer Center Houston, TX

Leslie S. Parran, RN, MS, AOCN, NE-BC, BMTCN University of Minnesota Medical Center Minneapolis, MN

J. Douglas Rizzo, MD, MS CIBMTR and Medical College of Wisconsin Milwaukee, WI

Jugna Shah, MPH Nimitt Consulting, Inc. Spicer, MN

S. Elizabeth Sharf, BSN, RN, NE-BC, CHTC University of North Carolina Chapel Hill, NC

Kent H. Walters, MBA UT MD Anderson Cancer Center Houston, TX

Invited Faculty HCT Value and Health Economics Session


David Dickens, MD Helen DeVos Children’s Hospital Grand Rapids, MI

Nathan J. Dowden Rubius Therapeutics Cambridge, MA

Kurt C. Gunter, MD Cell Medica Houston, TX

Lothar B. Huebsch, MD The Ottawa Hospital Ottawa, Canada

Richard T. Maziarz, MD Oregon Health & Science University Portland, OR

129129

Vinay Prasad, MD, MPH Oregon Health & Science University Portland, OR

Invited Faculty BMT Clinical Education Conference (for NPs, PAs, Fellows and Junior Faculty)Allistair Abraham, MD Children’s National Medical Center Washington, DC

Claudio Anasetti, MD H. Lee Moffitt Cancer Center and Research Institute Tampa, FL

Sonali Chaudhury, MD Lurie Children’s Hospital of Chicago Northwestern University Chicago, IL

Sung Won Choi, MD University of Michigan Ann Arbor, MI

Aamer Chughtai, MD University of Michigan Ann Arbor, MI

Corey S. Cutler, MD, MPH Dana-Farber Cancer Institute Boston, MA

Zachariah M. DeFilipp, MD Massachusetts General Hospital Boston, MA

Jackie Dioguardi, PA-C University of Michigan Ann Arbor, MI

Areej R. El-Jawahri, MD Dana-Farber Cancer Institute Boston, MA

Robert Peter Gale, MD, PhD Imperial College London London, United Kingdom

Randi Hoffmann, PhD, RN, CNP Medical University of South Carolina Charleston, SC

INV

ITE

D F

AC

ULT

Y

130130

Angela Kirk, PA-C Seattle Cancer Care Alliance Seattle, WA

Benjamin Laskin, MD, MS The Children’s Hospital of Philadelphia Philadelphia, PA

Paula Charuhas Macris, MS, RD, CSO Seattle Cancer Care Alliance Seattle, WA

Francisco M. Marty, MD Dana-Farber Cancer Institute Boston, MA

Lakshmi Nayak, MD Dana-Farber Cancer Institute Boston, MA

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN UT MD Anderson Cancer Center Houston, TX

Bart L. Scott, MD Fred Hutchinson Cancer Research Center Seattle, WA

Gregory A. Yanik, MD University of Michigan Ann Arbor, MI

Gabrielle Zecha, PA-C, MHA Fred Hutchinson Cancer Research Center Seattle, WA

Invited Faculty BMT Pharmacists ConferenceMarcos de Lima, MD University Hospitals Seidman Cancer Center and Case Western Reserve University Cleveland, OH

Amber Diaz, PharmD, BCOP Oregon Health Sciences University Portland, OR

Elizabeth DiMaggio, PharmD, BCOP H. Lee Moffitt Cancer Center and Research Institute Tampa, FL

131131

Kathy Hogan Edwards, PharmD, BCPS, BCOP Medical University of South Carolina Charleston, SC

Alex Ganetsky, PharmD, BCOP University of Pennsylvania Philadelphia, PA

Alison M. Gulbis, PharmD UT MD Anderson Cancer Center Houston, TX

Sonata Jodele, MD Cincinnati Children’s Hospital Medical Center Cincinnati, OH

Karissa Kusick Dominick, Pharm D BCOP Cleveland Clinic Cleveland, OH

Philip Lubanski, PharmD University of Kansas Hospital Kansas City, KS

Kelly E. Pillinger, PharmD Carolinas Medical Center Charlotte, NC

Anthony J. Proli, PharmD, BCOP, BCPS Memorial Sloan Kettering Cancer Center New York, NY

Kamakshi V. Rao, PharmD UNC Medical Center Chapel Hill, NC

Karen Sweiss University of Illinois at Chicago Chicago, IL

Colleen Timlin, PharmD University of Pennsylvania Health System Philadelphia, PA

Harrys A. Torres, MD UT MD Anderson Cancer Center Houston, TX

Laura Kay Whited, PharmD, BCOP MD Anderson Cancer Center Houston, TX

INV

ITE

D F

AC

ULT

Y

132132

Invited Faculty Transplant Nursing ConferenceAmin M. Alousi, MD UT MD Anderson Cancer Center Houston, TX

Kristen L. Beebe, PA-C Phoenix Children’s Hospital Phoenix, AZ

Brooke Cherven, RN, MPH, CPON Children’s Healthcare of Atlanta Atlanta, GA

George E. Georges, MD Fred Hutchinson Cancer Research Center Seattle, WA

Parameswaran N. Hari, MD, MS Medical College of Wisconsin Milwaukee, WI

Sharon R. Hymes, MD UT MD Anderson Cancer Center Houston, TX

Kyrie Hospodar Magee, CPNP, MSN, RN Phoenix Children’s Hospital/Mayo Clinic Arizona Phoenix, AZ

Rebecca Martin, BSN, RN, OCN, BMTCN Froedtert Hospital and The Medical College of Wisconsin Milwaukee, WI

Bernadette McLaughlin, BSN, RN Fred Hutchinson Cancer Research Center Seattle, WA

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN UT MD Anderson Cancer Center Houston, TX

Mary E. Peterson, MS, APRN, AOCNP Saint David’s South Austin Medical Center Austin, TX

Juan Pinelli, PA-C, MMSc Fred Hutchinson Cancer Research Center Seattle, WA

Cassandra Upchurch, BSN, RN Pennsylvania Hospital Philadelphia, PA

133133

Mary Victoria Weise, RN, BSN, OCN Mayo Clinic Phoenix, AZ

Invited Faculty Building a Patient-Centered Outcomes Research (PCOR) Collaborative CommunityBeatrice Abetti, LCSW Leukemia & Lymphoma Society White Plains, NY

Staci Arnold, MD, MBA Columbia University New York, NY


Ellen M. Denzen, MS National Marrow Donor Program/Be The Match Minneapolis, MN

Susan Doughtie, MS Georgia Cancer Center at Augusta University Augusta, GA

Rebecca J. Drexler CIBMTR, NMDP/Be The Match Minneapolis, MN

Areej R. El-Jawahri, MD Massachusetts General Hospital, Harvard Medical School Boston, MA

Mary M. Horowitz, MD, MS CIBMTR and Medical College of Wisconsin Milwaukee, WI

Mark B. Juckett, MD University of Wisconsin Madison, WI

Lakshmana Krishnamurti, MD Emory University Atlanta, GA

Alison W. Loren, MD, MSCE University of Pennsylvania Philadelphia, PA

INV

ITE

D F

AC

ULT

Y

134

Alva Roche-Green, MD Mayo Clinic Jacksonville, FL

Kim Schmit-Pokorny, RN, MSN, OCN, BMTCN Nebraska Medicine Omaha, NE

D. Kathryn Tierney, RN, PhD Stanford Health Care Stanford, CA

Christina Ullrich, MD, MPH Dana-Farber Cancer Institute Boston, MA

William A. Wood, MD, MPH University of North Carolina Chapel Hill, NC

135

All Committee Meetings Schedule-at-a-Glance(For CIBMTR Working Committee information, please refer to pages 108-109).

2018 PLANNING MEETINGS

CRP/DM Conference Planning Meeting for 2018 By Invitation Sun 2 Wednesday, February 22, 5:00 pm – 6:30 pm

BMT CTN Coordinators and Investigators Planning Meeting for 2018 By Invitation Sun 1 Thursday, February 23, 8:30 am – 10:00 am

Pediatric BMT Program Planning Meeting for 2018 By Invitation Sun 1 Friday, February 24, 7:00 am – 8:30 am

BMT Tandem Scientific Organizing Committee Meeting for 2018 By Invitation Orange Blossom Ballroom Saturday, February 25, 10:00 am – 11:30 am

Transplant Nursing Conference Planning Team Meeting for 2018 By Invitation Sun 1 Saturday, February 25, 4:00 pm – 6:00 pm

BMT Pharmacists Conference Planning Committee Meeting for 2018 By Invitation Osceola A Saturday, February 25, 5:00 pm – 6:00 pm

Clinical Education Conference Planning Committee Meeting for 2018 By Invitation Osceola C Saturday, February 25, 5:30 pm – 6:30 pm

AL

L C

OM

MIT

TE

E M

EE

TIN

GS

SC

HE

DU

LE

-AT-

A-G

LA

NC

E

136

SUBCOMMITTEE/BUSINESS MEETINGS

PBMTC Business Meeting and Reception Osceola A Thursday, February 23, 6:15 pm – 7:00 pm

CIBMTR General Assembly Florida Hall E Friday, February 24, 2:45 pm – 3:00 pm

ASBMT Business Meeting Open to All Attendees Florida Hall E Friday, February 24, 3:00 pm – 3:15 pm

ASBMT

ASBMT Committee on Cellular Therapy By Invitation St. George #112 Wednesday, February 22, 7:00 am – 8:00 am

ASBMT Committee on RFI By Invitation St. George #104 Wednesday, February 22, 7:30 am – 8:30 am

ASBMT Introduction/Orientation for Fellows-in-Training Open to All Attendees Sanibel 1-3 Wednesday, February 22, 10:00 am – 11:00 am

ASBMT Committee on Practice Guidelines By Invitation St. George #112 Wednesday, February 22, 6:45 pm – 7:45 pm

ASBMT Committee on Education By Invitation St. George #104 Thursday, February 23, 7:00 am – 8:30 am

ASBMT Palliative Care Special Interest Group By Invitation St. George #112 Thursday, February 23, 7:30 am – 8:30 am

ASBMT Past President’s Luncheon By Invitation St. George #112 Thursday, February 23, Noon – 1:30 pm

137

ASBMT Committee on Quality Outcomes By Invitation Emerald 1 Thursday, February 23, 12:15 pm – 1:15 pm

ASBMT Survivorship Research and Special Interest Group Meeting By Invitation Orange Blossom Ballroom Thursday, February 23, 12:30 pm – 2:15 pm

ASBMT Sub-Committee on Informatics By Invitation Emerald 1 Thursday, February 23, 1:15 pm – 2:15 pm

BBMT Editorial Board Meeting By Invitation St. George #106 Thursday, February 23, 1:30 pm – 3:00 pm

ASBMT Choosing Wisely Task Force By Invitation Emerald 6 Thursday, February 23, 2:00 pm – 3:00 pm

ASBMT Corporate Council Reception By Invitation Emerald Bay Plaza: Wedding Pavilion Thursday, February 23, 4:30 pm – 5:30 pm

ASBMT/CIBMTR/NMDP Leadership Meeting By Invitation St. George #106 Friday, February 24, 7:00 am – 8:30 am

ASBMT Infectious Disease Special Interest Group Meeting Open to All Attendees Sun 4-6 Friday, February 24, 7:00 am – 8:30 am

ASBMT Board of Directors Meeting By Invitation Orange Blossom Ballroom Friday, February 24, 10:30 am – 2:30 pm

Transplant Nursing Special Interest Group Steering Committee Meeting Open to All Attendees Osceola D Friday, February 24, 4:00 pm – 5:00 pm

AL

L C

OM

MIT

TE

E M

EE

TIN

GS

SC

HE

DU

LE

-AT-

A-G

LA

NC

E

138

ASBMT Special Interest Group Chair Meeting with President By Invitation St. George #104 Saturday, February 25, 7:30 am – 8:30 am

ASBMT Cord Blood Special Interest Group Meeting Open to All Attendees Tallahassee 1-3 Saturday, February 25, 12:15 pm – 2:15 pm

ASBMT Clinical Research Training Course Reunion By Invitation Emerald Bay Plaza: Wedding Pavilion Saturday, February 25, 1:30 pm – 2:30 pm

ASBMT NP/PA Special Interest Group Business Meeting Open to All Attendees Osceola C Saturday, February 25, 5:00 pm – 5:30 pm

CIBMTR

CIBMTR Advisory Committee Meeting By Invitation Osceola C Wednesday, February 22, 12:15 pm – 4:15 pm

Cell Therapy Registry Pilot Center Update Open to All Attendees St. George #108 Wednesday, February 22, 5:00 pm – 6:30 pm

Statistical Consulting with CIBMTR PhD Biostatisticians Open to All Attendees Sarasota 1 Thursday, February 23, 10:30 am – Noon

International Data Managers Open Forum Open to All Attendees St. George #108 Thursday, February 23, 1:00 pm – 3:30 pm

CIBMTR Consumer Advocacy Committee Meeting By Invitation Emerald 6 Thursday, February 23, 4:45 pm – 6:15 pm


139

Statistical Consulting with CIBMTR PhD Biostatisticians Open to All Attendees Sarasota 1 Friday, February 24, 10:30 am – Noon

WBMT Board Meeting By Invitation Miami 1-3 Friday, February 24, 10:30 am – 1:30 pm

LABMT – Latin America Blood and Marrow Transplant Group Open to All Attendees Tallahassee 1-3 Friday, February 24, 6:45 pm – 8:45 pm

CIBMTR Mismatched Unrelated Donor (15-MMUD) Transplant PI/Coordinators Meetings By Invitation Sanibel 1-3 Saturday, February 25, 7:00 am – 8:30 am

CIBMTR Kepivance Study Protocol Team Meeting By Invitation St. George #106 Saturday, February 25, 7:30 am – 8:30 am

FACT

FACT Standards Kick-Off Meeting By Invitation Emerald 1 Monday, February 20, 7:00 am – 5:00 pm

FACT Cellular Therapy Inspection and Accreditation Workshop Applicant Track Separate Registration Required Tallahassee 1-3 Tuesday, February 21, 7:00 am – 5:00 pm

FACT Cellular Therapy Inspection and Accreditation Workshop Inspector Track Separate Registration Required Sanibel 1-3 Tuesday, February 21, 7:00 am – 5:00 pm

FACT Cellular Therapy Leadership Course 101 Separate Registration Required Miami 1 Tuesday, February 21, 8:00 am – Noon

AL

L C

OM

MIT

TE

E M

EE

TIN

GS

SC

HE

DU

LE

-AT-

A-G

LA

NC

E

140

FACT Advanced Cellular Therapy Leadership Course 201 Separate Registration Required Miami 1 Tuesday, February 21, 1:00 pm – 5:00 pm

FACT Board of Directors Meeting By Invitation Daytona 1-2 Tuesday, February 21, 6:00 pm – 10:00 pm

FACT ASBMT Quality Boot Camp Open to All Attendees Miami 1-3 Wednesday, February 22, 7:00 am – 5:00 pm

Introduction to the FACT Accreditation Portal Open to All Attendees Separate Registration Required Daytona 1-2 Wednesday, February 22, 8:00 am – 10:00 am and Wednesday, February 22, 2:30 pm – 4:30 pm

FACT Clinical Outcomes Committee Meeting By Invitation Daytona 1-2 Wednesday, February 22, 10:30 am – Noon

FACT Consultants Meeting By Invitation Daytona 1-2 Wednesday, February 22, Noon – 1:00 pm

FACT Consultants Board of Directors Meeting By Invitation Daytona 1-2 Wednesday, February 22, 1:00 pm – 2:00 pm

FACT Global Affairs: Special Session for International Delegates Open to All Attendees Captiva 1-2 Wednesday, February 22, 5:00 pm – 7:00 pm

FACT Web Oversight Committee Meeting By Invitation Daytona 1-2 Wednesday, February 22, 6:45 pm – 8:00 pm

FACT CIBMTR Data Audit Meeting By Invitation Daytona 1-2 Thursday, February 23, 9:00 am – 10:30 am

141

FACT CAR T-Cell Task Force Meeting By Invitation Daytona 1-2 Thursday, February 23, 11:00 am – Noon

FACT Regenerative Medicine Task Force Meeting By Invitation Daytona 1-2 Thursday, February 23, Noon – 1:00 pm

Introduction to the FACT Accreditation Portal Day Two Open to All Attendees Separate Registration Required Daytona 1-2 Thursday, February 23, 1:00 pm – 3:00 pm and Thursday, February 23, 3:00 pm – 5:00 pm

Improving Clinical Outcomes with FACT Accreditation Open to All Attendees Sanibel 1-3 Friday, February 24, 7:30 am – 8:30 am

NMDP

BMT CTN Steering Committee Meeting By Invitation Osceola C Tuesday, February 21, 8:30 am – 5:00 pm

Radiation Injury Treatment Network (RITN) Annual Update Open to All Attendees Sanibel 1-3 Wednesday, February 22, 7:00 am – 8:30 am

Transplant Late Effects in Children (TLEC) Investigators Meeting By Invitation Orange Blossom Ballroom Wednesday, February 24, 7:00 am – 8:30 am

BMT CTN Myeloma Intergroup Meeting By Invitation Tallahassee 1-3 Wednesday, February 22, 6:45 pm – 8:45 pm

NMDP Transplant Center Networking Reception Open to NMDP/Be The Match Network Transplant Centers Only St. Augustine: Castillo de San Marcos Fort – Lower Level Wednesday, February 22, 7:00 pm – 9:00 pm

AL

L C

OM

MIT

TE

E M

EE

TIN

GS

SC

HE

DU

LE

-AT-

A-G

LA

NC

E

142

Orientation to CIBMTR/BMT CTN Open to All Attendees Naples 1-3 Thursday, February 23, 7:00 am – 8:15 am

RCI BMT Clinical Trials Advisory Committee (CTAC) Meeting By Invitation Orange Blossom Ballroom Thursday, February 23, 7:00 am – 8:30 am

BMT Data Standards and Interoperability By Invitation Sun 4-6 Thursday, February 23, 1:00 pm – 4:30 pm


Naïve T-Cell Depletion for Prevention of Chronic GVHD (NTCD) Investigators Meeting By Invitation Orange Blossom Ballroom Friday, February 24, 7:00 am – 8:30 am

NMDP Education Consortium Meeting By Invitation St. George #112 Saturday, February 25, 7:00 am – 8:30 am

Amy Strelzer Manasevit Research Program Reception By Invitation St. George #114 Saturday, February 25, 6:30 pm – 7:45 pm

143

SP

EC

IAL

TH

AN

KS

Special Thanks Support for the BMT Tandem Meetings has been generously provided by:

AABB 8101 Glenbrook Road Bethesda, MD 20814

Actinium Pharmaceuticals, Inc. 275 Madison Avenue, Suite 702 New York, NY 10016

Alexion Pharmaceuticals 100 College Street New Haven, CT 06510

Astellas Pharma US, Inc. One Astellas Way Northbrook, IL 60062

Biosafe America Inc. 1225 North Loop West, Suite 120 Houston, TX 77008

BloodCenter of Wisconsin 638 North 18th Street PO Box 2178 Milwaukee, WI 53201

BostonSight 464 Hillside Avenue, Suite 205 Needham, MA 02494

Celgene Corporation 86 Morris Avenue Summit, NJ 07901

Cerus Corporation 2550 Stanwell Drive Concord, CA 94520

Chimerix, Inc. 2505 Meridian Parkway Suite 100 Durham, NC 27713

City of Hope 1500 East Duarte Road Duarte, CA 91010

Coram CVS Specialty Infusion 555 17th Street, Suite 1500 Denver, CO 80202

DKMS 100 Broadway, 6th Floor New York, NY 10005

Feel Good, Inc. 1460 Gemini Boulevard, #8 Orlando, FL 32837

Foundation Medicine 150 Second Street, 1st Floor Cambridge, MA 02141

Fresenius Kabi USA, LLC 3 Corporate Drive Lake Zurich, IL 60047

Fresenius Medical Care 3500 Lacey Road Downers Grove, IL 60515

Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404

HistoGenetics 300 Executive Boulevard Ossining, NY 10562

Immudex 4031 University Drive, Suite 100 Fairfax, VA 22030

Incyte Corporation 1801 Augustine Cut-Off Wilmington, DE 19803

Janssen Biotech, Inc. 1000 U.S. Route 202 South Raritan, NJ 08869

Jazz Pharmaceuticals, Inc. 3180 Porter Drive Palo Alto, CA 94304

Karyopharm Therapeutics, Inc. 85 Wells Avenue, 2nd Floor Newton, MA 02459

Kashi Clinical Laboratories 10101 SW Barbur Boulevard Portland, OR 97219

Kite Pharma, Inc. 2225 Colorade Avenue Santa Monica, CA 90404

144

LabCorp 1440 York Court Burlington, NC 27215

LABS, Inc. 6933 South Revere Parkway Centennial, CO 80112

Management Science Associates, Inc. 6565 Penn Avenue Pittsburgh, PA 15206

Mediware Information Systems, Inc. 11711 West 79th Street Lenexa, KS 66214

Memorial Sloan Kettering Cancer Center 1440 York Avenue New York, NY 10065

Merck & Company 2000 Galloping Hill Road Kenilworth, NJ 07033

Millennium: The Takeda Oncology Co. 40 Landsdowne Street Cambridge, MA 02139

Miller Pharmacal Group, Inc. 350 Randy Road, Suite 2 Carol Stream, IL 60188

Miltenyi Biotec Friedrich-Ebert-Strabe 68 Bergisch Gladbach 51429 Germany

NanoEnTek USA, Inc. 5627 Stoneridge Drive Suite 304 Pleasanton, CA 94588

Nebraska Medicine 988132 Nebraska Medical Center Omaha, NE 68198-8132

Novartis Oncology One Health Plaza East Hanover, NJ 07936

Omeros Corporation 201 Elliott Avenue West Seattle, WA 98119

Oncology Nursing Certification Corporation 125 Enterprise Drive Pittsburgh, PA 15275

One Lambda, Inc., A Thermo Fisher Scientific Brand 21001 Kittridge Street Canoga Park, CA 91303

OriGen Biomedical 7000 Burleson Road, Building D Austin, TX 78744

OTTR Chronic Care Solutions, Inc. 10202 F Street Omaha, NE 68127

Oxford Immunotec 700 Nickerson Road, Suite 200 Marlborough, MA 01752

Pharmacyclics, LLC 999 East Arques Avenue Sunnyvale, CA 94085

Sandoz Biopharmaceuticals 100 College Road West Princeton, NJ 08540

Sanofi Genzyme 500 Kendall Street Cambridge, MA 02142

Sarah Cannon 1100 Charlotte Avenue Suite 800 Nashville, TN 37203

Seattle Cancer Care Alliance 825 Eastlake Avenue E Seattle, WA 98109

Seattle Genetics 21823 30th Dr. Southeast Bothell, WA 98021

Shire 300 Shire Way Lexington, MA 02421

Stafa Cellular Therapy 2201 Walnut Avenue, #208 Fremont, CA 94538

STEMSOFT Software, Inc. 401-570 West 7th Avenue Vancouver, BC V5Z 1B3 CANADA

145

SP

EC

IAL

TH

AN

KS

stemTrak 35 India Street Boston, MA 02110

Takeda Oncology 40 Landsdowne Street Cambridge, MA 02139

TeleResults Corporation 870 Market Street, Suite 556 San Francisco, CA 94123

TerumoBCT 10811 West Collins Avenue Lakewood, CO 80215

Texas Medical Specialty, Inc. 7777 Forest Lane Dallas, TX 75230

The Children’s Hospital of Philadelphia 34th Street and Civic Center Boulevard Philadelphia, PA 19026

University of Florida Health Shands Hospital 1600 SW Archer Road Gainesville, FL 32610

Viracor Eurofins 1001 Northwest Technology Drive Lee’s Summit, MO 64086

Additional thanks to the following organizations for their participation in the BMT Tandem Meetings:

BMT InfoNet 1548 Old Skokie Road, Suite 1 Highland Park, IL 60035

Foundation for the Accreditation of Cellular Therapy (FACT) 986065 Nebraska Medical Center Omaha, NE 68198-6065

National Bone Marrow Transplant Link (nbmtLink) 20411 West 12 Mile Road Suite 108 Southfield, MI 48076

NMDP/Be The Match 500 North 5th Street Minneapolis, MN 55413

Oncology Nursing Society 125 Enterprise Drive Pittsburgh, PA 15275

146

Gaylord Palms

Overview Map

Level Map

147

Convention Center Level 1

Florida Exhibition Hall

MA

PS

148

Convention Center Level 2

Sun and Osceola Ballrooms

149

MA

PS

Emerald Bay Lower Level

Emerald Bay Meeting Rooms

150

Emerald Bay Atrium Level

St. George Meeting Rooms

151151

MA

PS

Emerald Bay Atrium Level

Palm Beach and Orange Blossom

152152

Emerald Bay Fourth Floor

Executive Boardrooms

153153

Abbreviations

ACCME Accreditation Council for Continuing Medical Education

ACPE Accreditation Council for Pharmacy EducationAE Adverse EventAML Acute Myeloid (Myelogenous) LeukemiaaGVHD Acute Graft-Versus-Host DiseaseALL Acute Lymphoblastic LeukemiaALWP Acute Leukemia Working PartyAMA American Medical AssociationANCC American Nurses Credentialing CenterAPP(s) Advanced Practice Professional(s)ASCT Autologous Stem Cell Transplant ASBMT American Society of Blood and Marrow

TransplantationATG Anti-thymocyte GlobulinBBMT Biology of Blood and Marrow TransplantationBKV BK VirusBMT Bone Marrow TransplantationBMT CTN Blood and Marrow Transplant Clinical Trials

NetworkCAC Consumer Advocacy CommitteeCAR Chimeric Antigen ReceptorCB Cord BloodCE Continuing EducationCEU Continuing Education UnitCIBMTR Center for International Blood and Marrow

Transplant ResearchCLL Chronic Lymphocytic LeukemiaCME Continuing Medical EducationCMS Centers for Medicare and Medicaid ServicesCML Chronic Myeloid (Myelogenous) LeukemiaCMV CytomegalovirusCNE Continuing Nursing EducationCNS Central Nervous SystemCOG Children’s Oncology GroupCPI Continuous Process ImprovementCRP/DM Clinical Research Professionals/Data

ManagementCY CyclophosphamideEBMT European Group for Blood and Marrow

TransplantationEBV Epstein-Barr VirusFACT Foundation for Accreditation of Cellular TherapyGMP Good Manufacturing Practice A

BB

RE

VIA

TIO

NS

154

GVHD Graft-Versus-Host DiseaseGVL Graft-Versus-LeukemiaHCT Hematopoietic (Stem) Cell TransplantationHHV Human Herpes VirusHL Hodgkin LymphomaHLA Human Leukocyte AntigenHLH Hemophagocytic LymphohistiocytosisI-BFM International BFM Study GroupIBMTR International Bone Marrow Transplant RegistryIRB Institutional Review BoardJAK Janus KinaseKIR Killer Cell Immunoglobulin-like ReceptorsLABMT Latin America Blood and Marrow TransplantationMACRA Medicare Access and CHIP Reauthorization Act

of 2015MCW Medical College of WisconsinMDS Myelodysplastic SyndromeMF MyelofibrosisMIPS Merit-Based Incentive Payment SystemMMUD Mismatched Unrelated Donor TransplantationMRD Minimal Residual DiseaseNABP National Association of Boards of PharmacyNCDB National Cancer DatabaseNHL Non-Hodgkin LymphomaNK Natural Killer (Cell)NMDP National Marrow Donor ProgramONS Oncology Nursing SocietyPBMTC Pediatric Blood and Marrow Transplant

ConsortiumPBSCT Peripheral Blood Stem Cells TransplantationPCOR Patient-Centered Outcomes ResearchPCORI Patient-Centered Outcomes Research InstitutePDWP Pediatric Diseases Working PartyPROMIS Patient-Reported Outcomes Measurement

Information SystemPTCy Post-Transplantation CyclophosphamideRCI BMT Resource for Clinical Investigation in Blood

and Marrow TransplantationRFI Request for InformationRITN Radiation Injury Treatment NetworkSAA Severe Aplastic AnemiaSCD Sickle Cell DiseaseSCT Stem Cell TransplantationSF Short FormSIG Special Interest GroupSPEP Serum Protein ElectrophoresisTA-GVHD Transfusion-Associated Graft-Versus-Host

Disease

155

TAM Transplant-Associated Microangiopathy TEM Transverse Electro-MagneticTKI Tyrosine Kinase InhibitorTMA Thrombotic Microangiopathy TX TransplantUPEP Urine Protein ElectrophoresisVOD Veno-Occlusive DiseaseVZV Varicella-Zoster VirusWBMT Worldwide Network for Blood and Marrow

Transplantation

AB

BR

EV

IAT

ION

S

156

Notes

BMT Tandem Meetings

February 21-25, 2018Salt Lake City, Utah

Comprehensive Update on Blood and Marrow Transplantation

• Laboratory Research • Clinical Investigations • Patient Care

Early Registration & Abstract Deadline: October 3, 2017

Online Registration & Abstract Submission: www.cibmtr.org or www.asbmt.org

You are invited to

Mambo for Myelomaat the BMT Tandem Annual Meetings!Sanofi Genzyme will make a donation of up to $10,000 to support ASBMT and CIBMTR.

Follow us on Facebook and Twitter throughout the congress.#IMambo4Myeloma

This offer is subject to Sanofi Genzyme’s discretion and is subject to change at any time. This offer runs through February 26, 2017.US.PLE.16.12.003 © 2002-2017 sanofi -aventis U.S. LLC. All rights reserved.

Join us at Booth 100/102 to fi nd out more about how you can support.

Facebook “f” Logo CMYK / .eps Facebook “f” Logo CMYK / .eps

Facebook.com/ Sanofi Genzyme

@Sanofi Genzyme

or˛anˆˇ - center for international blood and marrow ...€¦ · transplant nurses, clinical...

Documents